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Multidisciplinary management of 
patients with metastatic colorectal 
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Colorectal cancer
Colorectal cancer is the third most common malignant tumor worldwide.[1] Each year, 
nearly 1,25 million patients are diagnosed with this disease, with an incidence of 14.000 
people in the Netherlands in 2018.[2] Approximately 50% of patients develop metastases 
during the course their disease, resulting in a relatively high overall mortality of 40-45%. 
Globally, more than 600.000 people die from colorectal cancer every year, mainly from 
metastatic disease.[1] 
Systemic therapy
Before the era of chemotherapy patients with mCRC had a median overall survival of 9 
months. [3] With the introduction of the chemotherapeutic agents fluoropyrimidines, 
oxaliplatin and irinotecan and targeted agents against VEGF and the EGF receptor in 
systemic treatment in combination and/or sequential administration has improved 
overall survival to over 30 months in most recent randomized phase III trials. [4-9] Trials 
investigating Regorafenib (multikinase inhibitor) and trifluridin/tipiracil (nucleoside 
analogue) have shown modest PFS improvement compared to best supportive care.[10, 
11] Moreover, immunotherapy has demonstrated benefit in patient with DNA mismatch 
repair-deficient tumors [12]. For the subgroup of patients with BRAF mutated tumors, 
combination therapy of BRAF and MEK inhibiting agents with chemo and/or anti-EGFR 
targeted agents are registered.[13, 14]
Originally, when patients presented with metastases, the disease was viewed as always 
being widespread and patients have typically been treated with systemic therapy. In time, 
patients with indolent course of disease and having a better prognosis were identified. 
Consensus on criteria of this so called ‘oligometastatic disease’ is lacking, but is typically 
characterized by a low number of lesions, limited organ sites, metachronous presentation, 
no involvement of lymph nodes and slow rate of progression.[15] With the possibility of 
cure, ablative therapies for these metastases is increasingly performed.
Local treatment
Local treatment of metastases is technically feasible in an increasing number of patients 
with mCRC by either resection, radiofrequency ablation or stereotactic radiotherapy. For 
patients with metastases limited to the liver, resection (± thermal ablative interventions) 
with curative intent is currently the standard of care.[16-18] For selected patients with 
oligometastatic extrahepatic mCRC, metastasectomy is performed based on the 
retrospective reports showing long-term survival. 
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a. Surgical resection
Liver metastases
Patients with limited liver-only disease have shown long survival times (5 year OS of 
40-60%) after resection of liver metastases.[19-21] With long term results available in 
this patient category, resection of liver metastases has become standard of care.[16-19] 
In non-randomized, retrospective and often single-center series, results for resection 
of metastases in patients with colorectal cancer with liver metastases and extrahepatic 
disease is reported. [22-27] Patients with adrenal gland or para aortic lymph node 
metastases appeared to have poor prognosis despite resection.[28, 29]
Lung metastases 
Resection of pulmonary metastases is being performed in patients with oligometastastic 
CRC. Clinical practice is based on consensus on the basis of a large number of observational 
studies, the largest being the report of the International Registry of lung metastases [30] 
but no reported data from randomized trials are available. After complete resection of 
pulmonary metastases 5-year survival rates of 40-68% can be achieved.[30-33]
Peritoneal metastases
Patients with peritoneal carcinomatosis generally have a poor prognosis, but this 
improved with the introduction of hyperthermic intraperitoneal chemotherapy (HIPEC) 
combined with extensive cytoreductive surgery for patients with limited disease, typically 
characterized by a PCI of less than 17.[34, 35]
b. Stereotactic ablative radiotherapy
Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation 
therapy or radiosurgery, is a modern radiation technique that delivers high doses of 
radiation to small tumor targets and is used to target lesions in the lungs, brain, liver, 
adrenals, and bone, among other locations. This is increasingly applied in the treatment 
of cancer metastasis. [36-41] High rates of local control are reported and the minimal 
invasiveness makes it an attractive treatment modality in cancer care. No phase 3 
randomized controlled trials are available for data on effect on overall survival. Published 
series usually combine different tumor types or locations of metastasis and do not correct 
for the use of systemic therapy.
c. Radiofrequency ablation (RFA)
Radiofrequency ablation is an interventional radiology technique, involving thermal 
ablation and can be performed both in an open (surgical) or percutaneous procedure 
under general anesthesia. In the treatment of colorectal cancer metastasis, this is mainly 
applied for treating lung and liver metastase. Usually ablation techniques are combined 
with resection of metastasis in one procedures. A randomized phase II trial to evaluate 
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the added value of RFA of liver metastases when combined with chemotherapy versus 
chemotherapy alone showed a median OS of 45.3 months for combination therapy versus 
40.5 months for systemic treatment alone, so the benefit of RFA remained uncertain.
[42] Multiple series and a Cochrane review have suggested beneficial effects in selected 
patients.  [43-47] A randomized trial to prove non-inferiority of thermal ablation compared 
to hepatic resection in patients with at least one resectable and ablatable colorectal liver 
metastasis and no extrahepatic disease is ongoing. [48]
Multidisciplinary care
As becomes clear from the above, colorectal cancer care is characterized by 
multidisciplinary treatment. Patients discussed in multidisciplinary meetings seem to 
have more accurate diagnoses than patients diagnosed by a single physician. Treatment 
plans are changed in >10% and generally adhere better to existing guidelines when 
discussed in the MDT.[49, 50] Galata et al. described that there was a high prevalence 
of patients with oligometastatic disease (of various primary tumors, 26% mCRC), and 
more than 50% local treatment of metastasis was recommended. [51] Although all this 
suggests that multidisciplinary team discussions improve patient care, improved survival 
has not been established yet. [52, 53] The key word for further improvement of prognosis 
is collaboration. Survival benefit should be pursued by multidisciplinary management 
leading to personalized medicine in terms of adequate patient selection for specific 
systemic therapies, treatment targeting the tumor or specific tumor characteristics as 
well as making a tailor-made treatment plan for local treatment of metastases, applying 
available treatment modalities by surgeons, radiotherapist and interventional radiologists.
There is increasing experience with all different available techniques. The remaining 
challenge is to use the right treatment modality or combination for the right patient 
including the use of chemotherapy. For colorectal cancer it is unknown if  patients with 
more extensive disease will benefit from this more aggressive approach. Evidence is 
needed from a randomized trial and in depth study of tumor characteristics. 
Part One: Debulking in metastatic colorectal cancer
Preliminary and retrospective evidence suggests that patients with extensive multi-organ 
mCRC may also benefit from local treatment of metastases. This results in a growing 
debate in multidisciplinary teams on whether local treatment of metastases should be 
performed in these patients. In Chapter 2, the rationale of debulking therapy for patients 
with multi-organ mCRC is reviewed.
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This ‘tumor debulking’ strategy should be considered as a palliative treatment approach, 
because even  after macroscopic complete resection, the disease will recur in the vast 
majority of patients. [22-24, 26] There is a clinical need for evidence from randomized 
trials evaluating whether tumor debulking results in survival benefit while maintaining 
the quality of life, when added to palliative systemic therapy in patients with extensive 
multi-organ mCRC.
The ORCHESTRA trial is the first multicenter randomized clinical trial in which 
multidisciplinary local treatment in addition to first line palliative systemic treatment 
is being evaluated (NCT01792934) as first line palliative treatment. Thirty-two Dutch 
hospitals participate in this trial, aiming to include 478 patients to demonstrate a 6 
months overall survival benefit in the intervention arm. Although ample experience has 
been gained with the various ablative therapies, limited data is available on combining 
different modalities in patients with extensive disease combined with the use of systemic 
therapy. Therefore a preplanned safety and feasibility evaluation was performed after 
completion of study treatment of the first 100 patients enrolled in the trial and reported 
in Chapter 3. 
Part Two: Predicting response to systemic therapy
Obviously, there is a clinical need for a biomarker with independent additional value 
that will predict response to first line systemic therapy. If response to treatment can be 
predicted with clinically relevant sensitivity and specificity prior to starting systemic 
therapy, unnecessary treatment can be withheld and toxicity prevented for patients with 
mCRC. Furthermore, alternative treatment strategies can be considered for these patients. 
A translational study program was embedded in the ORCHESTRA trial protocol and blood 
and tissue samples were collected from all patients enrolled.
MicroRNA
MicroRNAs (miRNAs) are small non-coding RNAs that have an impact on many important 
biological processes by regulation of protein expression levels. In addition, miRNAs have 
favorable biomarker characteristics as they are easy to detect and resistant to degradation. 
Studies have shown that tissue miRNAs are differentially expressed between normal 
and tumor tissue and between tumor subtypes. Furthermore, it has been observed that 
miRNAs from tumor cells are secreted into the circulation and could be detected in blood 
plasma and serum [54, 55]. Previous studies have shown significant correlations between 
circulating miRNAs and tumor stage and between paired tissue and serum miRNA 
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expression levels [56, 57]. These circulating miRNAs could function as a minimally invasive 
predictive biomarker and as biomarker for disease monitoring. 
Previously, we developed a model to predict response to palliative systemic treatment in 
patients with mCRC based on primary tumor expression of miRNAs and clinicopathological 
factors. Six miRNAs (miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and 
miR-98-5p) combined with four clinical parameters (the use of adjuvant chemotherapy 
after resection of the primary tumor, age, tumor differentiation and type of systemic 
treatment i.e. oxaliplatin or irinotecan based) were predictive for clinical benefit with an 
AUC of 0.78 [58]. Furthermore, we demonstrated that expression profiles of primary CRC 
tissues and metastatic lesions were highly comparable [59]. 
We aimed to prospectively validate the predictive value of the previously identified miRNA 
signature in the patients enrolled in the ORCHESTRA trial, which is reported in Chapter 4.
Circulating Endothelial Cells (CECs)
Circulating endothelial cells (CECs) are cells detached from both damaged normal 
vasculature as well as tumor vasculature. Compared to healthy controls, CEC values are 
frequently elevated in patients with disseminated malignancies. Previously, it has been 
shown that in patients with metastatic cancer, CEC numbers at baseline and changes 
in CEC numbers during systemic therapy are associated with prognosis. Consequently, 
enumeration of CEC is considered a promising biomarker in oncology [60]. However, 
limited data is available on the value of CECs in predicting treatment response. Measuring 
tumor-derived CECs could increase specificity and improve predictive value in cancer. 
Tumor cells express low levels of CD276, but tumor associated endothelial cells express 
high levels. Kraan et al.  developed a flowcytometry based detection assay for tumor 
derived CD276+ CECs, differentiating CECs from normal and malignant vasculature, which 
enables to distinguish a subpopulation of CECs coming from malignant vasculature in 
patients with advanced malignancies.[60, 61] In Chapter 5 the results of (CD276+)CECs 
measurements from patients enrolled in the ORCHESTRA trial are reported. The primary 
objective of the study was to establish the prevalence of CD276+CECs in patients with 
mCRC and evaluating the dynamics of CD276+CECs during systemic therapy. Furthermore 
we evaluated the association of (CD276+) CEC counts with clinical parameters. We aimed 
to determine a clinically relevant cut-off value of the absolute count of CD276+CECs at 
baseline with 100% sensitivity for patients with progressive disease within 6 months of 
first line palliative systemic therapy, with a specificity of 80% included in the confidence 
interval. 
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Zr89-labeled PET Imaging 
In Chapter 6 a completely different approach to predicting response to therapy is taken. 
Here,  Zr89-labeled PET Imaging is used to acquire more insight in the body distribution of 
cetuximab,  a monoclonal antibody targeting the EGF receptor. In Dutch guidelines, the use 
of cetuximab is recommended therapy for patients with RAS and BRAF wild type tumors, 
with the exception of right sided primary tumors. [62-67]  However, despite selection based 
on mutational status, still one-third of patients do not benefit from anti-EGFR treatment.  
Variability in pharmacokinetics of the antibody may play a role in its clinical efficacy. 
EGFR is highly expressed on hepatocytes, possibly leading to sequestration of anti-EGFR 
mAbs in normal liver tissue. This may result in insufficient circulating anti-EGFR mAbs 
to reach tumor lesions, prohibiting antitumor activity. We hypothesized that response 
to treatment is dependent on uptake of cetuximab in tumor lesions. We performed 
89Zr-cetuximab PET imaging in patients with wt K-RAS mCRC with an indication for anti-
EGFR mAb monotherapy to investigate biodistribution and tumor uptake as well as to 
establish the optimal scanning time point to visualize tumor targeting. Most importantly, 
we evaluated whether uptake on 89Zr-cetuximab PET imaging can discriminate between 
patients responding to treatment with cetuximab versus non-responding patients.
In Chapter 7 the main findings presented in this thesis are summarized and discussed.
A Dutch summary of this thesis is given in the Appendices, that also hold a curriculum 
vitae of the PhD candidate,  a list of publications and acknowledgements.
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Abstract
Local treatment of metastases by surgical resection or other ablative therapies is 
technically feasible in an increasing number of patients with multi-organ metastatic 
cancer. This results in a growing debate on whether patients with extensive disease, that is 
traditionally deemed unresectable, may benefit from local treatment of metastases when 
added to standard palliative systemic therapy. For selected patients with oligometastatic 
colorectal cancer, local treatment of metastases has become the standard of care based 
on retrospective reports showing longterm survival rates. In addition to systemic therapy, 
preliminary evidence suggests that patients with extensive metastatic colorectal cancer 
may also benefit from local treatment. Here, we present the future perspectives based on 
the available literature on local treatment approaches in colorectal cancer.
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Background
Local treatment of metastases by surgical resection or ablative techniques is technically 
feasible in an increasing number of patients with multi-organ metastatic colorectal cancer 
(mCRC). This results in a growing debate in multidisciplinary teams on whether local 
treatment of metastases should be performed. For patients with metastases confined 
to the liver, resection with curative intent is currently the standard of care. For selected 
patients with oligometastatic extrahepatic mCRC, metastasectomy is performed based 
on the retrospective reports showing longterm survival. Preliminary and retrospective 
evidence suggests that patients with extensive multi-organ mCRC may also benefit from 
local treatment of metastases. This ‘tumor debulking’ strategy should be considered as a 
palliative treatment approach, because even  after macroscopic complete resection, the 
disease will recur in the vast majority of patients. [1-4] There is a clinical need for evidence 
from randomised trials evaluating whether tumor debulking results in survival benefit 
while maintaining the quality of life, when added to palliative systemic therapy in patients 
with extensive multi-organ mCRC.
Colorectal cancer metastases
The dissemination pattern of  CRC from localised towards extensive metastatic disease can 
be considered as a continuum in which the possibility of curation reduces with the extent 
of the disease (Figure 1). Both the stage of the disease at the time of diagnosis and the 
underlying biological characteristics of the malignancy constitute important prognostic 
factors. Metastatic patterns may reflect tumor biology and impact prognosis.[5, 6] For 
example the presence of peritoneal carcinomatosis in patients with CRC is associated with 
a worse overall survival compared with patients without the peritoneal involvement of 
CRC [7]. At diagnosis, micrometastases are already present in a subset of patients with 
localised CRC and in the majority of patients with oligometastases (reflected by the 
dotted line). Currently, surgical resection is mainly preserved for patients who are treated 
with curative intent (approximately 20% of the patients with liver metastases), while in 
a palliative setting, resections are only indicated to alleviate or prevent symptoms. In 
patients with mCRC confined to the liver, resection of liver metastases can lead to longterm 
survival rates of approximately 40%. Although not formally proven in a randomised 
clinical trial, this approach is generally accepted as an effective treatment strategy with a 
curative intent.[8-11] Approximately one in six patients are actual 10-year survivors and 
can be considered to be cured. Molecular markers, such as BRAF and KRAS mutations, are 
associated with poor prognosis after resection of colorectal liver metastases (CLMs) [12, 
13].
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Figure 1: Resection or debulking in CRC
Different stages of colorectal carcinoma, CRC with no positive lymphnodes (stage I and II), pathological 
lymphnodes present (stage III and stage IV disease), separated in liver and oligometastases and 
multi-organ extrahepatic disease (≥ 2 different organs with ≥ extrahepatic lesions)
Solid line showing the chance of curability and the dashed line showing the chance of 
presence of micrometastases. CRC, colorectal cancer. EHD, extrahepatic disease.
Local treatment modalities
Developments in surgical procedures, combination with local ablative techniques and 
the use of induction chemotherapy have increased the number of patients for whom 
local treatment of metastases is feasible. Multiple local treatment strategies, such as 
thermal ablation (radiofrequency ablation [RFA], Microwave ablation [MWA]), irreversible 
electroporation (IRE; NanoKnife), local radioembolisation techniques (with or without 
cytotoxic or radiolabeled agents) and stereotactic ablative radiotherapy (SABR) are 
developing rapidly and finding their way into clinical practice. [14, 15] 
 
Thermal ablation techniques such as  RFA or MWA are the most frequently used non-
surgical technique for local treatment of liver metastases. The CLOCC trial is the only 
randomised controlled trial in which the added value of RFA was investigated in patients 
with unresectable  CLMs treated with chemotherapy.[16] After almost 10 years of follow-
up, the 3-, 5- and 8-year OS was 55.2%, 30.3% and 8.9% in the systemic treatment arm 
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versus 56.9%, 43.1% and 35.9% in the combination therapy arm, respectively. Median 
OS was 45.6 months in the combination therapy arm versus 40.5 months in the systemic 
treatment arm. It should be noted that in 45% of patients in the intervention arm, RFA 
was combined with resection. [17] Observational studies comparing hepatic resection 
with RFA show 5-year OS from 19 to48% but are hampered by important imbalance 
among characteristics of patients.[18] IRE, causing destruction of tumor cells by electrical 
impulses, is currently being investigated in phase II studies for multiple cancer types and 
localisations, and not standard of care yet.[15] 
In CRC, SABR is mainly used for lung metastasis or unresectable liver lesions that are also 
deemed unsuitable for thermal ablation. A prospective study showed a 2-year local control 
rate of 74% in 20 consecutively treated patients with colorectal hepatic metastases. [19] 
Retrospective, single-centre series also indicated promising local control and OS data of 
patients who were deemed ineligible for (or refused) surgery or RFA. [20] In 82 patients 
with one to three inoperable metastases in liver or lung, the 3-year local control rate was 
75% and the OS was 43%[21].
The benefit of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) 
and adjuvant chemotherapy compared with systemic chemotherapy alone was 
studied by Verwaal et al. in a randomised controlled trial in patients with peritoneal 
carcinomatosis of CRC[22]. Patients treated with cytoreductive surgery  plus HIPEC and 
systemic chemotherapy had an improved median survival of 22.3 months compared with 
12.6 months for patients treated with systemic chemotherapy alone  (p = 0.032). Long-
term survival does not seem to be improved as seen by follow-up results.[23]  
One of the most crucial aspects to define the optimal strategy of therapy for patients with 
mCRC is the evaluation on a case-by-case basis in an expert multidisciplinary team. [8] 
Solid evidence supporting decision-making is unavailable and hardly any randomised 
trials comparing local treatment modalities with each other or with systemic therapy 
have been performed. Owing to the comparable results from observational studies of 
local treatment modalities, one can assume that large patient populations are needed to 
demonstrate clinical significant differences in OS or statistically significant non-inferiority. 
In daily clinical practice, it seems increasingly difficult to randomise patients for local 
treatment versus standard systemic treatment, because of the lack of clinical equipoise in 
both patients and treating physicians.
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Local treatment in multi-organ mCRC
By far the most debated contraindication to treatment of CLMs is the presence of 
extrahepatic disease. For selected patients with  extrahepatic oligometastases, a local 
treatment strategy is considered potentially curative based on retrospective reports. 
[1, 2, 4] Pulitanò et al.  reported from an international multi-institutional database on 
1629 patients who underwent resection of CLMs , from which 10.4% had resection from 
extrahepatic disease.  If survival was stratified by the total number of metastases treated, 
the presence of extrahepatic disease still had a negative prognostic impact, but the relative 
impact of extrahepatic disease diminished as the total number of metastases treated 
increased. [24] Hadden et al. published a review and meta-analysis on resection of CRC 
liver metastases and extra-hepatic disease, including 15144 patients (from 52 studies), 
of which 2308 patients had extrahepatic disease.[1] The 5- year OS rates were 26% , 17% 
and 15% for extrahepatic lung,  peritoneum and lymphnode involvement, respectively. 
Although this is substantially lower than the reported 5- year survival rates for patients 
with liver metastases only, it does suggest that in a subset of patients with extrahepatic 
disease tumor debulking may provide the possibility of long-term survival. Park et 
al. studied the role of palliative resection in mCRC  in a retrospective cohort, including 
1015 patients with mCRC.[25] One hundred sixty-eight patients with only liver and/or 
lung metastasis received curative resection. Of the remaining 847 patients, 527 received 
palliative resection (R0 resections in 93 patients and R1/2 resections in 434 patients) 
and standard chemotherapy. The median OS rates were 51.3 months, 19.1 months 
and 14.1 months for R0 resected, R1/2 resected and unresected patients respectively. 
In the subgroup analysis, the benefit from palliative resection was not significant in 
older patients or patients with a poor Eastern Cooperative Oncology Group  (ECOG) 
score. This suggests that if metastases are potentially resectable and the performance 
status of the patients is ECOG 0-1, tumor debulking may be a good treatment option. 
Based on the available data, unequivocal patient selection criteria have not been 
established.  Predictive models derived from retrospective series are suggested, but 
validation studies are lacking and they are currently not used in clinical practice. 
Tumor debulking
There are theoretical benefits of tumor debulking in patients with extensive disease, 
but thus far there are no clinical data to support this. One could postulate that organ 
dysfunction could possibly be prevented by reduction of tumor burden, thereby improving 
the performance status and tolerance of systemic therapy. In addition, after removal of 
poorly vascularised tumors and drug-resistant clonal cells, the limited tumor residue may 
be better perfused making it more responsive to cytotoxic agents. Moreover, reduction of 
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the total tumor mass may alleviate the associated immunosuppressive effects and thereby 
enhance host immunocompetence, all potentially improving overall survival.[26, 27] 
Despite the lack of mechanistic proof, the combination of tumor debulking and 
chemotherapy is an evidence-based standard of care or advanced ovarian cancer.[28] 
Critics emphasise, however, that the biological behaviour and extent of disease at diagnosis 
are leading in the course of the disease. Moreover it is speculated that the immediate 
postoperative low immune status and growth factors released after ablative interventions 
may actually facilitate the tumor growth. Practical issues in considering the role of tumor 
debulking in extensive disease include the fact that effective systemic treatment needs 
to be interrupted for local treatment to take place.  Procedure-related morbidity and 
mortality, although improved by supportive care and development of minimal invasive 
techniques for local treatment, may impact the quality of life and performance status of 
patients. 
Solid evidence showing favourable PFS or OS while maintaining the quality of life 
is, therefore, required to make these local treatment strategies part of the standard 
palliative treatment in combination with systemic treatment for patients with extensive 
multi-organ mCRC. The way forward may be to explore tumor debulking in patients 
irrespective of complete resectability of the disease.[8] This could range from resecting 
the primary tumor only to local treatment of all metastatic lesions. For patients with 
mCRC, comparison of local treatment of metastases with modern palliative systemic 
treatment including combination chemotherapy with 5-fluorouracil (5-FU) and oxaliplatin 
or irinotecan and antivascular endothelial growth factor or anti- epidermal growth factor 
receptor monoclonal antibodies resulting in a median OS of up to 30 months is lacking at 
this point. [29] 
Trials in progress
Several study groups have evaluated the role of tumor debulking in extrahepatic mCRC. 
Both in the Netherlands (NCT01606098), France (NCT02363049; NCT02314182), Germany 
(ISRCTN30964555) and in China (NCT02149784), multicentre randomised phase III trials 
are recruiting patients with synchronous unresectable metastases of CRC and randomising 
between systemic therapy only and resection of the primary tumor followed by systemic 
therapy. In the multicentre phase III ORCHESTRA trial1 patients with multi-organ CRC 
metastases are randomised between the combination of chemotherapy and maximal 
tumor debulking by a combination of surgery, radiotherapeutics or thermal ablation 
1  The Principle Investigators of the Orchestra trial are the key authors of this manuscript. 
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(at least 80% of tumor lesions is considered to be resectable), versus chemotherapy 
alone (NCT01792934). Safety and feasibility are demonstrated after inclusion of 100 
patients. The LUNA trial (NCT02738606) is a phase II single-institution randomised trial 
randomising patients with resectable liver metastases and unresectable (but low volume) 
lung metastases between liver resection plus chemotherapy and chemotherapy without 
liver resection. 
Conclusion
Solid evidence by randomised clinical trials is needed to evaluate whether patients with 
extensive mCRC will benefit when tumor debulking approaches are combined with 
standard palliative systemic therapy because most of the clinical data concerning tumor 
debulking in mCRC are derived from the retrospective analysis.
Although local treatment of metastases might be feasible with current local treatment 
modalities in an increasing number of patients with mCRC, only overall survival benefit 
while maintaining the quality of life can confirm that this is the preferred palliative 
treatment approach. Several ongoing trials will provide clinical evidence for this approach 
and will improve multidisciplinary decision-making in patients with mCRC.
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Abstract
Local treatment of metastases is frequently performed in patients with multi-
organ metastatic colorectal carcinoma (mCRC) analogous to selected patients with 
oligometastatic disease for whom this is standard of care. The ORCHESTRA trial 
(NCT01792934) was designed to prospectively evaluate overall survival (OS) benefit from 
tumor debulking in addition to chemotherapy in patients with multi-organ mCRC. Here, 
we report the preplanned safety and feasibility evaluation after inclusion of the first 100 
patients. 
Patients were eligible if at least 80% tumor debulking was deemed feasible by resection, 
radiotherapy and/or thermal ablative therapy. In case of clinical benefit after 3 or 4 cycles 
of respectively 5-fluorouracil/leucovorin or capecitabine and oxaliplatin ± bevacizumab 
patients were randomized to tumor debulking followed by chemotherapy in the 
intervention arm, or standard treatment with chemotherapy. 
Twelve patients dropped out prior to randomization for various reasons. Eighty-eight 
patients were randomized to the standard (N = 43) or intervention arm (N = 45). No 
patients withdrew after randomization. Debulking was performed in 82% (N = 37). Two 
patients had no lesions left to treat, 5 had progressive disease and one patient died prior 
to local treatment. In 15 patients (40%) 21 serious adverse events related to debulking 
were reported. Postoperative mortality was 2.7% (N = 1).  After debulking chemotherapy 
was resumed in 89% of patients. 
In conclusion tumor debulking is feasible and does not prohibit administration of palliative 
chemotherapy in the majority of patients with multi-organ mCRC, despite the occurrence 
of serious adverse events related to local treatment. 
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Introduction
In the current multidisciplinary approach of metastatic colorectal cancer (mCRC), local 
treatment of oligometastases is increasingly performed. Large series of selected patients 
with liver-only metastases treated with complete surgical resection suggest that this 
approach improves 5-year survival rates to around 30-60%, and offer the only potential for 
cure.[1-4] Application of techniques such as radiofrequency or microwave ablation (RFA, 
MWA) or stereotactic ablative radiotherapy (SABR) potentially increase feasibility of local 
treatment of metastases.[5-9]  
For selected patients with oligometastatic colorectal cancer (mCRC), local treatment of 
metastases is standard of care based on retrospective reports showing long term survival 
rates. However, reports on the benefit of local treatment for multi-organ metastases of 
CRC were non randomized, single-center and retrospective and therefore hampered by 
selection bias.[10-16] Treatment options with curative intent are generally not available 
for patients with extensive hepatic and/or extrahepatic mCRC. These patients primarily 
receive palliative systemic treatment consisting of combination chemotherapy with agents 
targeting VEGF or EGFR.[17, 18] It is unknown whether patients with extensive disease will 
benefit from tumor debulking when added to first line palliative systemic therapy.[19, 20] 
The benefit from local treatment of multi-organ metastases for these patients should be 
evaluated prospectively. Attempted prospective randomized studies were challenged by 
a lack of clinical equipoise, where both patient and doctors had preferences for either 
treatment arm based on beliefs of respectively under or overtreatment.  
The ORCHESTRA trial (NCT01792934) is a randomized trial, designed to prospectively 
evaluate overall survival (OS) benefit from tumor debulking by resection, radiotherapy 
and/or thermal ablative therapy in patients with multi-organ mCRC when added to 
palliative systemic therapy.[21] The current manuscript reports on the preplanned safety 
and feasibility evaluation of tumor debulking based on the first 100 patients included. 
This trial examines the interplay of both efficacy and toxicity for the combination of 
systemic chemotherapy and local therapy. The study design incorporates both systemic 
and local therapy in the experimental arm and combines local treatment modalities to 
pursue maximal tumor debulking. The aim is to improve overall survival with at least six 
months of patients with multi-organ mCRC by maximal tumor debulking in addition to 
palliative chemotherapy.
In case this trial meets its primary outcome of 6-months overall survival benefit, it will 
provide the evidence that any kind of local ablative therapy in a setting with multiple 
metastases will be of clinically significant benefit for patients with multi organ mCRC and 
could reasonably be extended to patients with oligometastatic mCRC.
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This report is focused on feasibility and safety of the local treatment procedures in this 
patient population. Moreover, we studied the ability to administer adequate palliative 
systemic treatment in the intervention arm, being the current evidence-based treatment 
regimen, compared to patients receiving standard palliative systemic therapy.
Methods
The ORCHESTRA trial is a randomized multicenter clinical trial for patients with multi-
organ mCRC, comparing the combination of chemotherapy and maximal tumor 
debulking versus chemotherapy alone.  All procedures performed involving human 
participants were in accordance with the ethical standards of the institutional ethical and 
research committee and with the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards.
Written informed consent was obtained from all patients included in the ORCHESTRA 
trial. Patients were 18 years or older and had an indication for first line palliative systemic 
therapy for mCRC. They all had an ECOG performance status of 0-2 and adequate bone 
marrow, liver and renal function.
Patients with extensive multi-organ mCRC were eligible, as specified in table 1. Tumor 
debulking of at least 80% of metastatic lesions by a combination of resection, radiotherapy 
or thermal ablative therapy was deemed feasible by a multidisciplinary team, including a 
specialist in surgical oncology, radiotherapy, radiology and medical oncology. Metastatic 
lesions were enumerated on CT scan. If peritoneal metastases were individual deposits, 
these were numbered as separate metastatic lesions. In case of diffuse peritoneal 
carcinomatosis where lesions were difficult to define, this was categorized as ‘diffuse 
disease’. If the number of lesions in a single organ exceeded 10, this was also categorized 
as diffuse disease. 
Table 1: Main eligibility criteria
ORCHESTRA Eligible patients
Patients with CRC metastases in ≥ 2 different organs if at least
>1 extrahepatic metastases or
>5 hepatic metastases not located to one lobe or
either a positive para-aortal lymph nodes or celiac lymph nodes or adrenal metastases or pleural 
carcinomatosis or peritoneal carcinomatosis
NB The primary tumor is excluded as metastatic site
Feasible radical tumor debulking. Incomplete tumor debulking is allowed only if at least 80% of metastases 
can be locally treated. 
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Patients who underwent prior local treatment were not excluded. Prior (adjuvant) 
systemic therapy should have been completed more than 6 months at diagnosis of 
extrahepatic metastatic disease. Comprehensive in and exclusion criteria are available 
at clinicaltrials.gov (NCT01792934). All patients received systemic therapy consisting of 
5 Fluorouracil / Leucovorin (5-FU/LV) or capecitabine with oxaliplatin ± bevacizumab at 
physician discretion. Systemic therapy consisted of orally administered capecitabine 1000 
mg/m2 twice a day for two weeks and oxaliplatin 130 mg/m2 intravenously (CAPOX) on 
day 1 in a 3-week cycle or comparable intravenous regimen consisting of oxaliplatin 85 
mg/m2 on day 1 and 400 mg/ m2 leucovorin (LV) followed by 400 mg/m2 5-FU bolus 
and 2400 mg/m2 continuous infusion over 46 hours (modified FOLFOX6) of each 2-week 
cycle. Bevacizumab was added at physician discretion as intravenous infusion over 30-90 
minutes on day 1 (in CAPOX regimen 3-weekly 7.5 mg/kg, in FOLFOX regimen biweekly 
5 mg/kg). First response evaluation (according to RECIST)[22] on a CT scan of thorax and 
abdomen was scheduled after 3 cycles of CAPOX(B) or 4 cycles of FOLFOX(B) (generally 9 
weeks). Follow up CT scans were done at least every 3 months. 
In case of stable disease or response, patients were randomized to continuation of 
systemic therapy (standard treatment; arm A), or tumor debulking followed by systemic 
therapy (intervention; arm B) and was stratified for location of metastases (liver and lung 
only versus other), number of metastatic sites (≥2 organs) and prior local treatment of 
metastases (yes/no) as well as gender, baseline LDH (normal or elevated) and response to 
3 cycles of systemic treatment (stable disease versus (partial) response).
Patients who were randomized in the intervention arm and had stable disease at first 
evaluation, continued systemic therapy (3 cycles of CAPOX(B) or 4 cycles of FOLFOX(B)) 
followed by debulking if disease remained stable. Bevacizumab was omitted in the 
treatment cycle prior to tumor debulking. The final local treatment plan was determined 
by the multidisciplinary team based on metastases present at the latest CT scan. 
Based on operating reports and radiotherapy treatment delivery, the number of treated 
metastases was documented and classified as tumor debulking of > 80% of metastatic 
lesions or not.
Adverse events (AE) were documented according to Common Terminology Criteria for 
Adverse Events (CTCAE version 4.03) and documented to be related to systemic therapy 
(only >grade 2), local therapy or not related. AEs related to local treatment were  graded 
according to the Clavien Dindo classification of surgical complications as well.[23] Serious 
Adverse Events (SAE) were reported to the competent authority for adverse events that 
resulted in death, were life-threatening, required inpatient hospitalization or caused 
prolongation of existing hospitalization, resulted in persistent or significant disability/
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incapacity or required intervention to prevent permanent impairment or damage. Safety 
reports were drawn up and evaluated by an independent Data Safety Monitoring Board 
after inclusion of 25, 50 and 100 patients.  Study continuation was based on the interim 
report on safety and feasibility after inclusion of 100 (of 478) patients. 
A 20% drop out rate prior to randomization due to progression on first line systemic 
therapy or other reasons was taken in to account in the power analysis. A total of 478 
patients are anticipated to be included to randomize 382 patient and meet the primary 
endpoint of an overall survival benefit of > 6 months (power 80%, type I error rate 5%). 
The study was deemed feasible if less than 10% of patients would withdraw from the 
study after randomization of 20% of the total number of patients (N=76). Secondary 
endpoints include progression free survival and quality of life, as well as evaluation of 
potential biomarkers such as CEA, microRNA (miRNA), circulating endothelial cells and 
platelet derived RNA.
Results
Between May 2013 and May 2015, the first 100 patients were included in 16 secondary and 
tertiary hospitals in the Netherlands that are part of the Dutch colorectal cancer group 
(DCCG). Patients had a median age of 65 years (range 30-78) and 67% were male. Of these 
100 patients, 71% had a left sided primary tumor and 63% presented with synchronous 
metastatic disease. In 72% the primary tumor was resected, and 34 patients had prior 
local treatment of metastases. In 35% more than 2 organs were involved in metastatic 
disease (up to 5 organs). Patients had a median of 6 metastatic lesions (Interquartile range 
(IQR) 5). Twenty-six percent had <5 lesions, 43 % had 5-10 lesions, and 31% had more 
than 10 lesions or diffuse (peritoneal) disease. There were no significant differences in 
clinical parameters between both treatment arms prior to start of chemotherapy (Table 
2). Liver metastases were present in 81%, 50% had lung metastasis and 57% had distant 
lymphnode metastases, from which 60% at a poor prognostic site.[12, 24] Peritoneal 
disease was present in 33%, and respectively 7%, 5% and 3% had bone, adrenal gland or 
skin/ subcutaneous metastases. The majority of patients were treated with CAPOX, one 
patient was treated with FOLFOX.  Bevacizumab was added in 62%. Seventy percent of 
patients in arm A and 64% of patients in arm B completed 8 cycles of CAP(OX).
Prior to randomization, two patients went off study due to toxicity of systemic treatment, 
two patients deceased, and five patients withdrew consent before starting or during the first 
cycles of systemic therapy (no reason specified). Three patients had progressive disease and 
were not randomized per protocol.  Eighty-eight patients were randomized to the standard 
(N=43) or intervention arm (N=45). No patients withdrew after randomization (Fig. 1).
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Patients with multi-organ mCRC
80% debulking deemed feasible
(n = 100)
 ARM B           n = 45 ARM A            n = 43 











3 x CAPOX(B)a or 4 x FOLFOX(B)b
 
Withdrawal of consent (5)
Toxicity of systemic treatment (2)
Died (2)
Progressive disease (3)




PDd during systemic tx (2)
PDd awaiting debulking (3)
Died(1)
Figure 1: Consort Diagram
a CAPOX (B)= capecitabine and oxaliplatin (bevacizumab); bFOLFOX (B) = 5-fluorouracil/ leucovorin 
and oxaliplatin (bevacizumab)
c CR = Complete Response; d PD = Progressive Disease 
44   |   Chapter 3













Gender: Male 67 (67) 29 (67) 31 (69) 0.88
Age <65 51 (51) 25 (58) 21 (47) 0.28
Synchronous 63 (63) 30 (70) 26 (58) 0.24
Left sided primary tumor 71 (71) 26 (60) 35 (78) 0.08
Primary in situ 28 (28) 14 (41) 12 (27) 0.55
Number of metastases 0.89
<5 26 (26) 11 (26) 10 (22)
5-10 43 (43) 18 (42) 21 (47)
>10 or diffuse 31 (31) 14 (33) 14 (31)
Number of organs involved 0.35
2 65 (65) 29 (67) 26 (58)
>2 35 (35) 14 (33) 19 (42)
CEAa >5 ug/l 78 (78) 31 (79) 37 (84) 0.18
LDHb normal 77 (77) 37 (86) 34 (65) 0.28
Prior tumor treatments
Prior (neo) adjuvant chemotherapy 19  9 (21)  10 (22) 0.88
Prior chemoradiation 14 4 (9) 8 (17) 0.25
Previous local treatment 34 17 (40) 12 (27) 0.20
aCEA = Carcinoembryonic antigen; bLDH = Lactic Acid Dehydrogenase
Debulking
In Table 3, local treatment details of patients in arm B are summarized. Protocol debulking 
was performed in 37 (82%) patients. In 14 patients debulking was performed with one 
single modality, the other patients required combined modalities. Four patients (11%) 
were treated by three modalities (surgery, RFA and radiotherapy). In 31 patients (69%), 
debulking of ≥80 % of metastatic lesions was achieved. The total duration of hospital 
admission in days was median 9 (IQR 15). This included elective hospital admissions 
for surgery and (percutaneous) RFA and unplanned readmissions (7 patients; 16%). In 
seven patients (16%) a colostomy was created as part of the debulking procedure. In 
five patients with liver metastases hemihepatectomy was needed as part of debulking, 
14 patients had wedge resections or segmentectomy and in 12 (43%) patients RFA was 
used peroperatively. Radiotherapy was administered in an outpatient setting. Patients 
had a median of 6 radiotherapy sessions (IQR 10). The median total local treatment days 
including hospital admission and radiotherapy visits was 14 days (IQR 19).
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Table 3: Local treatment characteristics of patients in intervention arm B
Local treatment characteristics n (%)
Intervention arm  45 (51%)
Debulking performed 37 (82%)
At least 80% treated 31 (69%) 
Number of modalities, median (range) 2 (1-3)
One modality
Surgery only 8 (21.6)
Radiotherapy only 4 (10.8)
RFAa only 2 (5.4)
Two modalities
Surgery and RFAa 6 (16)
Surgery and Radiotherapy 11 (29.7)
RFAa and Radiotherapy 2 (5.4)
Three modalities: Surgery and RFA and Radiotherapy 4 (10.8)
Total hospital local treatment days (surgical admission, (unplanned) readmissions, RTb sessions 
and/or percutaneous RFA treatment), median (IQRc)
 4 (19)
aRFA = radiofrequency ablation; bRT = radiotherapy; cIQR = Interquartile range
In 13% of patients in arm B, debulking was not performed due to progressive disease 
(N=5) or death (N=1) prior to local treatment. Two patients who had stable disease 
at randomization, progressed during the following courses of systemic therapy and 
debulking was not performed as per protocol. Two patients showed progressive disease 
awaiting local treatment (one patient with a newly diagnosed brain metastasis, one 
patient with progressive and unresectable liver metastases). One patient’s disease was 
unresectable because of unexpected finding of extensive peritoneal carcinomatosis at 
laparotomy. One patient died in a motor vehicle accident prior to local treatment. On 
imaging prior to debulking, two patients had near complete response, with lesions too 
small to treat after systemic therapy (Fig. 1).
Adverse Events
A total of 77 serious adverse events (SAEs) were reported in 50 patients of the cohort of 
100 patients. Thirty-two events occurred prior to randomization in 25 patients.  In arm A, 
17 events occurred (in 11 patients) and 28 in arm B (in 21 patients). In arm A, 6 SAEs were 
related to systemic therapy and 11 were not related. Of the SAEs in arm B, 1 was related to 
systemic therapy, 6 were unrelated, and 21 were related to local treatment (in 15 patients; 
Table 4). In arm B, all adverse events (AEs) in surgical debulking were documented (Table 
5) and graded according to the Clavien Dindo classification of surgical complications 
(Table 6). Thirty-two complications were reported in 19 patients (51%), from which 11 (in 9 
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patients; 24%) were ≥ grade 3 according to Clavien Dindo. Postoperative 90-day mortality 
was 2.7% (N = 1; hepatic failure). One other patient deceased from respiratory insufficiency 
due to pneumonitis, which was possibly related to the stereotactic radiotherapy treatment 
that the patient underwent 11 months before. 
Table 4: Systemic Therapy
Parameter Arm A  
(n = 43), n  (%)
Arm B 
(n = 45), n  (%)
Systemic therapy
Chemotherapy
CAPOXa 42 (98) 45 (100)
FOLFOXb 1 (2) 0
Bevacizumab 25 (58) 30 (67)
Completed equivalent of 8 cycles CAP(OX)a 30 (70) 29 (64)
Response at first evaluation
Complete remission 0 (0) 1 (2)
Partial Remission 21 (48) 20 (44)
Stable Disease 22 (51) 24 (53)
Progressive disease n/a n/a
aCAPOX = capecitabine and oxaliplatin; bFOLFOX = 5-fluorouracil/ leucovorin and oxaliplatin
Table 5: Serious adverse events * 






All SAEs 11(26)a 21(47)b
Not related 7 (16) 6 (13)
Related to chemotherapy 5 (12) 1 (2)
Related to local treatment n/a 15 (33)
90-day mortality n/a 1 (2.7)
aIn arm A, one event grade > 3* 
 bIn arm B, four events grade > 3*; and two events grade 5*
*according to CTCAE: Common Terminology Criteria for Adverse Events version 4.03  
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Table 6: Adverse events of debulking procedures ≥ grade 3 according to Clavien Dindo 
classification of surgical complications.







Biliary anastomotic leak/ duct leakage (3x)
4 Ileus
5 Hepatic failure
Chemotherapy was resumed in 89% of patients.  Four patients who did not resume 
chemotherapy all had stable disease at randomization and therefore completed 7 (of 8) 
cycles of CAPOX prior to debulking.  One patient could not restart due to complications of 
debulking, one did not restart the first line systemic treatment due to progressive disease. 
In the other 2 patients, the treating physician did not restart because the patients had 
no evaluable disease left and no symptoms to palliate after debulking had taken place. 
Altogether, 83% of patients who underwent debulking completed (the equivalent of ) 8 
cycles CAP(OX). In general, 70% of patients in arm A and 64% of patients in arm B (p 0.65) 
completed the equivalent of 8 cycles of CAP(OX) (Table 4). 
The median time to restart systemic treatment was 12.5 weeks (IQR 6.75) after completion 
of the last preoperative cycle of systemic therapy. The median interval between the last 
debulking event and restarting systemic therapy was 5 weeks (IQR 6).
Discussion
The current report shows that tumor debulking is safe and does not prohibit administration 
of palliative chemotherapy in the majority of patients with multi-organ mCRC. Completing 
tumor debulking had substantial impact for the patients involved. Inevitably, serious 
adverse events occurred.  The morbidity and  90-day mortality is comparable to previous 
studies on surgical resection of CRC liver metastases.[25-29] Patients randomized in arm 
B who underwent debulking after 7 cycles of systemic therapy, due to stable disease at 
first evaluation, did not have more SAEs related to the procedures despite having received 
more cycles of chemotherapy.[30]
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This initial evaluation also demonstrates that it is feasible to prospectively include and 
randomize patients with metastatic colorectal cancer (mCRC) between palliative systemic 
treatment and tumor debulking combined with palliative systemic treatment. It was 
challenging to get consensus on feasibility of tumor debulking, which may potentially 
be hampered by a lack of clinical equipoise of members in the multidisciplinary team. 
Commitment and close collaboration grew in time in the participating centers that 
include patients. 
To our knowledge, only one prospective study on patients with resection for extrahepatic 
disease has been published by Wei et al. This phase II study of metastasectomy for both 
intrahepatic and extrahepatic disease enrolled 26 patients with generally less extensive 
disease (median 1 extrahepatic organ involved with a median of 2 extrahepatic lesions) 
and reported 19% major morbidity and 4% mortality.[29] 
There is heterogeneity in the different local treatment techniques used for tumor 
debulking which may influence outcome. However, limited randomized data on direct 
comparison of the different local treatment techniques is available and the individual 
techniques show acceptable local control rates. [20, 31] In the study protocol we defined 
surgical resection of metastatic lesions as the preferred local treatment. Depending on 
the location and size of the metastasis, thermal ablation or radiotherapy were considered.
No patients withdrew from ORCHESTRA study participation after randomization. Three 
patients developed disease progression in the interval between chemotherapy and 
resection (6.7%) and were excluded from local treatment. This is less than described by 
Vigano et al. for patients with resectable colorectal liver metastases awaiting resection. The 
reported early disease progression (<8 weeks) occurring in approximately 15% of patients 
who underwent liver resection and had extremely poor survival after liver resection (0% 
at 2 years). To prevent tumor progression and poor oncological outcome we aimed for a 
short chemotherapy free interval.[28] Systemic therapy was resumed within a median of 
12.5 weeks after finishing preoperative chemotherapy. There was a median of 5 weeks 
interval between last local treatment and start of postoperative chemotherapy, which 
could be considered a ‘morbidity associated chemotherapy interval’. In previous studies 
of patients undergoing two stage hepatectomy for resectable CRC liver metastases, the 
interval between pre and postoperative chemotherapy was median 18.7 weeks and 
median 9.8 weeks from the stage 2 resection.[26] In a series of patients who underwent 
major hepatectomy (≥3 segments) for mCRC, with 4% having extrahepatic disease, 
postoperative chemotherapy was given in 87%, starting median 6 weeks postoperatively.
[28]
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There was no significant difference in the amount of cycles of systemic therapy given 
between the study arms, and a comparable proportion of patients completed at least 8 
cycles of CAPOX(±B) (or the equivalent in FOLFOX) in both treatment arms. 
Conclusion 
The preplanned safety and feasibility report of the ORCHESTRA trial demonstrates that 
it is feasible to perform tumor debulking in patients with multi-organ mCRC without 
prohibiting administration of palliative systemic therapy, despite the occurrence of 
SAEs related to local treatment. This study addresses a topical issue in everyday practice 
of multidisciplinary CRC care with a study design compatible with current treatment, 
enabling the results to be readily implemented in daily practice. The ORCHESTRA trial will 
continue accrual to determine whether the primary aim of >6 months overall survival 
benefit of additional tumor debulking will be met. 
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Abstract 
Palliative systemic therapy is currently standard of care for patients with extensive 
metastatic colorectal cancer (mCRC). There is clinical need for a biomarker with 
independent additional value to clinical parameters in predicting early response to 
chemotherapy to prevent toxicity from ineffective treatment. 
In this study, a previously developed tissue-derived six microRNA (miRNA) profile to 
predict response to chemotherapy was evaluated in tissue biopsies and serum from 
patients with mCRC. Samples were prospectively collected from patients with mCRC (N 
= 132). Baseline tissue and serum miRNAs expression levels of miR-17-5p, miR-20a-5p, 
miR-30a-5p, miR-92a-3p, miR-92b-3p and miR-98-5p were quantified with RT-qPCR and 
droplet digital PCR, respectively. All patients were treated with capecitabine or 5-FU/LV 
with oxaliplatin ± bevacizumab. Response evaluation was performed according to RECIST 
1.1 after respectively 3 or 4 cycles. The combined predictive performance of selected 
variables was tested using logistic regression analysis. 
From 132 patients, 81 fresh frozen tissue biopsies from metastases and 93 serum samples 
were available for analysis. Based on expression levels of miRNAs in tissue, progressive 
disease could be predicted with an AUC of 0.85 (95% CI: 0.72-0.91) and response could 
be predicted with an AUC of 0.70 (95% CI: 0.56-0.80) This did not outperform clinical 
parameters alone (respectively p = 0.14 and p=0.27). Expression levels of miR92a and 
miR98 in serum significantly improved the predictive value of clinical parameters for 
response to chemotherapy (AUC 0.74, 95% CI: 0.64-0.84 versus AUC 0.67, 95% CI: 0.56-0.78, 
p=0.003) in this cohort, but remains insufficient for clinical decision making. 
In conclusion the predictive value of the tissue-derived six miRNA profile for response 
to chemotherapy could not be validated in patients with mCRC starting with first line 
systemic therapy. 
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Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that have an impact on many important 
biological processes by regulation of protein expression levels. In addition, miRNAs have 
favorable biomarker characteristics as they are easy to detect and resistant to degradation. 
Studies have shown that tissue miRNAs are differentially expressed between normal 
and tumor tissue and between tumor subtypes. Furthermore, it has been observed that 
miRNAs from tumor cells are secreted into the circulation and could be detected in blood 
plasma and serum (1, 2).
 
Since it is possible to reliably detect miRNAs in human blood specimens, interest has 
shifted towards using miRNAs as a liquid biomarker. Tumor specific miRNAs may be 
released into the blood circulation through active secretion in exosomes or through 
passive secretion by cell death (3). Patients with high tumor load are expected to have 
high levels of tumor specific circulating miRNAs (ci-miRNAs). Previous studies have shown 
significant correlations between ci-miRNAs and tumor stage and between paired tissue 
and serum miRNA expression levels (4, 5). These ci-miRNAs could function as a minimally 
invasive predictive biomarker and as biomarker for disease monitoring. 
Among cancer types, colorectal cancer (CRC) ranks in the top three for incidence and 
mortality worldwide (6, 7). Approximately half of all patients diagnosed with CRC will 
have metastasis at diagnosis or develop them during the course of their disease (8). For 
patients with extensive metastatic disease, no treatment with curative intent is available. 
Standard of care for these patients is palliative systemic treatment that usually consists of 
5-FU-based combination chemotherapy with oxaliplatin or irinotecan, anti-VEGF targeted 
therapy and anti-EGFR antibodies. Overall survival with these modern regimens is an 
estimated 30 months (9, 10). Currently, only for the use of anti-EGFR therapy a biomarker 
of response is available and it is recommended to exclude RAS and BRAF mutant tumors 
and right sided primary tumors from anti-EGFR therapy (11, 12). Since approximately 10 to 
20% of the patients do not benefit from first line chemotherapy and will have progressive 
disease at first evaluation, there is a strong clinical need for a predictive biomarker (9, 10, 
13, 14).
Previously, we developed a model to predict response to palliative systemic treatment in 
patients with mCRC based on primary tumor expression of miRNAs and clinicopathological 
factors. Six miRNAs (miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and 
miR-98-5p) combined with four clinical parameters (the use of adjuvant chemotherapy 
after resection of the primary tumor, age, tumor differentiation and type of systemic 
treatment i.e. oxaliplatin or irinotecan based) were predictive for clinical benefit with an 
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AUC of 0.78 (15). Furthermore, we demonstrated that expression profiles of primary CRC 
tissues and metastatic lesions were highly comparable (16). 
Three of these miRNAs (miR-17-5p, miR-20a-5p and miR-92a-3p) belong to the miR-
17-92 cluster, also known as oncomir-1. miRNAs from this cluster are involved in tumor 
angiogenesis, treatment resistance and CRC progression (17-20). The other miRNAs, 
miR-30a-5p, miR-92b-3p and miR-98-5p are involved in proliferation of CRC cells (21-23). 
In addition, high expression of miR-92b-3p has previously been related to a prolonged 
progression free survival in patients with mCRC treated with combined FOLFOX and 
bevacizumab (24). The current study aimed to prospectively validate the predictive value 
of the previously identified miRNA signature in a cohort of patients with extensive mCRC, 
starting first line palliative systemic therapy.
Material and Methods
Tissue and serum samples
Samples were prospectively collected as part of the translational study program of the 
ORCHESTRA trial between May 2013 and February 2017; the ORCHESTRA FF cohort. The 
ORCHESTRA trial is a randomized multicenter clinical trial for patients with multi-organ 
colorectal cancer metastases comparing the combination of chemotherapy and maximal 
tumor debulking versus chemotherapy alone (25). Comprehensive information and 
exclusion criteria are available at clinicaltrials.gov (NCT01792934).
Written informed consent was obtained from all patients included in the ORCHESTRA trial 
(26, 27). At baseline, 1 to 4 fresh frozen 14-18 G needle biopsies were obtained (ultrasound 
or CT guided) from a metastatic lesion or from the primary tumor (endoscopically). The 
biopsy specimen was transferred to a storage tin and snap frozen in liquid nitrogen and 
subsequently stored at -80°C until RNA isolation. Serum was collected in a BD vacutainer® 
tube, incubated upright for 1 hour and centrifuged at 1500 x g for 10 minutes at room 
temperature. Samples were aliquotted and stored at -80°C until RNA isolation. Specimens 
were collected prior to the start of systemic therapy.
Clinical parameters were documented and included age, gender, primary tumor sidedness 
(left or right), number of organs involved in metastatic disease, primary tumor in situ (yes 
or no), number of metastatic lesions (<5, 5-10, >10 or diffuse disease), differentiation 
(well/moderately, poor), prior (neo-) adjuvant chemotherapy (yes or no), CEA (elevated >5 
ng/µl, normal), LDH (elevated >250 ng/µl, or normal).
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All patients were treated with 5-FU/LV or capecitabine and oxaliplatin (46-hour continuous 
infusion of 5-FU/LV and oxaliplatin in a biweekly schedule (FOLFOX) or oxaliplatin IV 
followed by 14 days of oral capecitabine in a 3-week cycle (CAPOX)) ± bevacizumab at 
physician discretion. After 3 cycles of CAPOX(B) or 4 cycles of FOLFOX(B) a CT scan of 
thorax and abdomen was performed. Follow-up scans were performed at least every 3 
months and evaluated according to RECIST v 1.1 (28). 
RNA extraction 
Tissue
Dissection of fresh frozen biopsies was performed at approximately -25oC in a cryotome. 
Biopsies were enriched for tumor cells by macro dissection. Twenty µM sections were cut 
and snap-frozen in liquid nitrogen and stored at -80oC until RNA extraction. Multiple 5 µM 
sections were stained with hematoxylin and eosin (H&E) to confirm presence of tumor cells 
across the biopsy. As stromal infiltration is a characteristic for worse prognosis, stromal 
percentage was included into tumor purity estimation (29). The percentage of tumor field 
was defined as the sum of the percentage of tumor cells and the percentage of stromal 
cells. Samples were included if the percentage of tumor field was ≥30% as scored by a 
pathologist (NCT v G.). RNA was isolated using the AllPrep® DNA/RNA/miRNA Universal Kit 
(Qiagen, Venlo, The Netherlands) according to the manufacturers protocol, eluted in 30 µl 
nuclease free water and quantified using a Nanodrop 2000 (Thermo Scientific, Waltham, 
MA, USA).
Serum
Serum RNA was extracted using the miRNeasy Serum/Plasma advanced Kit (Qiagen, 
former Exiqon) (30). During RNA extraction a DNase step was included using the RNase-
Free DNase Set (Qiagen) according to the manufacturers protocol. 
Hemolytic index
The hemolytic index (HI) of serum samples was measured using the automated Roche 
Modular Cobas 8000 platform according to the instructions of the manufacturer. Serum 
samples with a HI ≥10 were excluded for further analysis, since blood cells contain a lot of 
miRNAs and significant correlations between the HI and expression of certain ci-miRNAs 
was demonstrated before (30, 31). 
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miRNA quantification
Tissue
miRNAs miR-16-5p, miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and 
miR-98-5p were quantified with reverse transcription quantitative PCR (RT-qPCR) and 
analyzed as previously described (15). The chemicals from Exiqon were replaced with the 
chemicals from Qiagen as Exiqon merged with Qiagen, using the miRCURY LNA RT kit for 
cDNA synthesis and the miRCURY LNA miRNA PCR assays together with miRCURY LNA 
SYBR® Green for miRNA quantification (Qiagen). Cq values were normalized with miR-16-
5p as described by Livak end Schmittgen et al. (32). 
Serum 
cDNA synthesis was performed with the miRCURY LNA RT kit (Qiagen) using 3 µl extracted 
RNA. Serum RNA quality was assessed by measuring synthetic miRNA spike-in of cel-miR-
39-3p with RT-qPCR as described above using cel-miR-39-3p miRCURY LNA miRNA PCR 
assay (Qiagen). Samples were selected for droplet digital PCR (ddPCR) analysis if the raw 
Cq value was ≤30 (30). cDNA was diluted 1:40 for ddPCR. Each ddPCR reaction consisted 
of 9.9 µl diluted cDNA, 11 µl of QX200 EvaGreen ddPCR Supermix (Bio-Rad, Veenendaal, 
The Netherlands) and 1.1 µl optimal concentration miRCURY LNA miRNA PCR assay. The 
optimal PCR assay concentration was experimentally assessed for each assay using 1.0 
µl, 0.5 µl and if necessary 0.25 µl assay diluted in nuclease free H 2O (supplemental figure 
S1A). A gradient (52oC – 62oC) ddPCR was performed for each assay to define the optimal 
annealing temperature (supplemental figures S1B). Similar PCR assays were used as 
described in the paragraph on miRNA quantification (tissue). 
Twenty µl ddPCR reaction mix and subsequently 70 µl QX200TM droplet generation oil 
for EvaGreen (Bio-Rad) was loaded on a DG8TM Cartridge for QX200TM/QX100TM droplet 
generator. Droplets were generated in a QX200TM droplet generator and a total of 40 µl 
was loaded in a ddPCRTM 96-Well PCR plate (Bio-Rad). Each plate included a non-template 
control (NTC) and positive control for each PCR assay with H2O and RNA from cancer cell 
lines as described previously.(15) The PCR reaction was performed in a Thermal cycler 
(Bio-Rad) with a 3-step protocol; 1) Enzyme activation: 5 minutes at 95oC, 2) PCR: 30 
seconds at 95oC and 1 minute at primer specific annealing temperature repeated 40 times, 
3) droplet stabilization: 5 min 4oC, 5 min 95oC, and at 4oC until droplet reading. Droplets 
were quantified in a Droplet Reader QX200TM (Bio-Rad) and the number of formed droplets 
was obtained using QuantaSoft software (Bio-Rad). If less than 10,000 droplets were 
formed, the PCR reaction for that particular sample was repeated. Threshold estimation to 
define positive and negative droplets together with absolute miRNA quantification was 
performed using the R-package “ddpcRquant” designed by Trypsteen and colleagues (33). 
The standard “ddpcRquant” package was designed for single plate analysis. Because the 
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number of samples in this study exceeded the number of wells of a single 96-well plate, the 
script was adapted to analyze multiple plates for the same assay. The final concentration 
in copies per µl cDNA was log2 transformed and normalized for technical variation with 
log2 transformed cel-miR-39-3p levels as described above. 
Statistical analysis
Predicting response after 3-4 cycles of chemotherapy was tested for two scenarios (1) 
clinical benefit (CB) defined as complete response (CR), partial response (PR) and stable 
disease (SD) together versus progressive disease (PD) and 2) CR or PR versus SD or PD. 
The models for response prediction as designed previously (15) were tested with the 
combined miRNA expression and clinicopathological data collected from the current 
cohort (ORCHESTRA FF cohort). New prediction models were formed for different clinical 
endpoints with multivariate logistic regression analysis using Akaike’s information 
criterion (AIC)-based backward selection for selection of the best model. For the new 
prediction models the clinical parameter “type of systemic treatment” was excluded 
because all patients in the ORCHESTRA FF cohort received the same systemic treatment. 
Performance of the models was evaluated by comparing AUCs of paired ROC curves 
(clinicopathological factors versus added value of the miRNA expression to these factors) 
as described before (15). 
As the prediction co-efficients of the miRNAs from the models in the previous study 
(original FFPE cohort) are based on its miRNA expression levels, the miRNA expression 
levels in the ORCHESTRA FF cohort were compared with the expression levels in the 
original FFPE cohort (15). Because the ORCHESTRA FF cohort consisted only of patients 
with stage IV disease, and the original FFPE cohort consisted of patients with stage I to 
IV disease, the miRNA expression data from the original FFPE cohort was grouped in 
stage I-III and IV disease. Two comparisons were performed: 1) miRNA expression levels 
between stage I-III and IV in the original FFPE cohort and 2) miRNA expression between 
stage IV in the original FFPE cohort and stage IV in the ORCHESTRA FF cohort. The Welch’s 
two sample t-test or Two sample t-test were used for these comparisons. 
Baseline characteristics from the patients in the ORCHESTRA FF cohort were compared to 
the baseline characteristics from the patients in the original FFPE cohort (15), as well as 
for the patients from the serum and tissue cohorts in the ORCHESTRA FF cohort. Fishers 
Exact 2-sided test, Pearson 2-sided Chi-Square test or an unpaired t-test were used to test 
significance in baseline characteristics between the different cohorts. P values <0.05 were 
considered statistically significant. Log2 normalized expression data was used to correlate 
serum versus tissue miRNA expression data. Unsupervised cluster analysis was performed 
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with log2 transformed normalized serum and tissue miRNA expression levels using ward.
D2 clustering and Manhattan distance. Statistical analysis were performed using the 
R-package “CompareGroups” using R studio (version 1.1.423) with R software (version 
3.5.0) downloaded from Bioconductor (34-36).
Results
From May 2013 to March 2017, 132 patients with mCRC were included in the ORCHESTRA 
trial and available for analysis. From 29 patients no baseline tissue biopsy was available 
and from 12 patients, no baseline serum sample was available. From the available tissue 
samples, 22 were excluded due to a tumor-field percentage <30%. From 120 available 
serum samples 27 were excluded due to a hemolytic index > 10 (n=24), hemolytic index 
not assessable (n=2) or poor RNA quality (n=1) (Fig. 1A). No significant differences were 
observed between the clinicopathological characteristics from the tissue cohort (N = 81) 
and the serum cohort (N = 93) (Supplementary Table S1). Tumor field percentage ranged 
from 30% to 100% with a median of 100% (Fig. 1B). Of the included samples in the tissue 
cohort 53 (65%) were from liver metastases. Biopsies were collected from eight different 
organs (Fig. 1C). Unsupervised cluster analysis of log2 transformed normalized tissue 
miRNA expression data revealed two specific clusters. These clusters were not related to 
tumor field percentage (categorized in 30 -50%, 51-80% and 81-100%), location of the 
primary tumor (left vs right sided), tumor-site biopsy (liver vs other) and location of the 
primary tumor (rectum vs colon) (Fig. 1D).
In the serum cohort, raw Cq values of cel-miR-39-3p quantified with RT-qPCR ranged from 
26 to 30 with a median of 28 (Fig. 1E). Unsupervised cluster analysis of log2 normalized 
serum miRNA expression data showed that cluster membership was not correlated to 
biopsy side, left or right sided tumors, hemolytic index or primary tumor location. In 
serum, high miRNA expression was observed for miR-92a-3p, miR-20a-5p and miR-17-5p, 
whereas low expression was observed for miR-30a-5p, miR-92b-3p and miR-98-5p (Fig. 
1F).
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Figure 1: Sample flow chart, sample characteristics and miRNA expression. 
A) Sample flow chart of the included serum and tissue biopsies. B) Percentage of tumor field (tumor 
stroma plus tumor cells) per biopsy. C) Location of the different biopsies included in the tissue cohort. 
D) Unsupervised cluster analysis of log2 normalized tissue miRNA expression levels. E) RNA quality 
control of RNA extracted from serum samples using cel-miR-39-3p expression levels quantified with 
RT-qPCR. F) Unsupervised cluster analysis of log2 normalized serum miRNA expression levels. HI: 
Hemolytic index.
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Response prediction 
Tissue 
Using the miRNA expression levels from the ORCHESTRA fresh-frozen (FF) cohort combined 
with the age, tumor differentiation, use of adjuvant chemotherapy after primary resection 
and type of palliative systemic therapy in the previously validated models revealed low 
predictive value for treatment response. Using the predictive model for CR and PR versus 
PD resulted in an AUC of 0.60, 95% CI, 0.35-0.85, and using the predictive model for CR and 
PR versus SD resulted in an AUC of 0.51, 95% CI, 0.37-0.64 (15).
Prediction of clinical benefit versus progressive disease at first evaluation by measured 
microRNA expression levels revealed a model with an AUC of 0.85 (95% CI: 0.72-0.91) (Fig. 
2A). This model included expression levels of miR-17-5p, miR-92b-3p and miR-98-5p. The 
AUC of this model is higher compared to the AUC of the model with the parameters age, 
tumor differentiation and prior use of adjuvant chemotherapy alone (AUC: 0.74, 95% CI, 
0.56-0.92), but did not reach statistical significance (p = 0.14). The calculated predicted 
probabilities from the model are visualized in figure 2B. Addition of miRNA expression 
levels to the clinicopathological covariates did not significantly improve the performance 
of the model to discriminate between patients with response (CR and PR) (n=37) versus 
SD and PD (n=44), (AUC: 0.67, 95% CI:0.55-0.79 versus AUC: 0.70, 95% CI:0.56-0.80 with 
miRNAs, p = 0.27) (Fig. 2C), with a wide range of predicted probabilities (Fig. 2D). 
Serum
In the serum cohort, logistic regression analysis could not be performed, because only 
three patients showed progressive disease after 3 to 4 cycles of chemotherapy. When 
separating the study cohort in objective response (CR or PR) versus SD and PD after 3 to 4 
cycles of chemotherapy, a model with miR-92a-3p and miR-98-5p expression combined 
with previous adjuvant chemotherapy and tumor differentiation had a significant better 
performance compared to the model with clinicopathological factors alone (AUC 0.74, 
95%CI 0.64-0.84 versus AUC 0.67, 95%CI 0.56-0.78; p=0.003) (Fig. 3A). The calculated 
predicted probabilities are visualized in figure 3B. From 58 patients, tissue and serum 
expression data were available. There was no correlation between tissue and serum 
expression of these six miRNAs (Fig 3C). 
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Figure 2: Performance of the predictive models in the tissue cohort. 
A) ROC curve for clinical benefit (n=76) versus progressive disease (n=5) after 3 to 4 cycles of 
chemotherapy. Dotted line: the model with clinicopathological factors. Solid line: the re-estimated 
model of the clinicopathological factors combined with miRNA expression levels. B) Predictive 
probability for CB versus PD calculated with the model with the solid line from Fig. 2A (miR-17-5p, 
miR-92b-3p and miR-98-5p). C) ROC curve for CR and PR (n=37) versus SD and PD (n=44) after 3 to 4 
cycles of chemotherapy. D) Predictive probability for CR and PR versus SD and PD calculated with the 
model presented with the solid line from Fig. 2C (differentiation, miR-92b-3p). 
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Figure 3: Performance of the predictive models in the serum cohort. 
A) ROC curve analysis for prediction of CR/PR (n=46) versus SD/PD (n=47) after 3 to 4 cycles of 
chemotherapy in the serum cohort. Dotted line: the model without miRNAs. Solid line: the model 
with miRNAs. B) Individual predicted probabilities of the model with miRNAs for CR/PR versus SD/
PD after 3 to 4 cycles of chemotherapy. AUC: area under the curve, PR: partial response, SD: stable 
disease, PD: progressive disease. C) Correlation plot of log2 normalized tissue miRNA expression 
levels (x-axis) and log2 normalized serum miRNA expression levels (y-axis). Data is presented for miR-
17-5p only, similar results were observed for other miRNAs (data not shown).
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Comparison with the original formalin fixed paraffin 
embedded (FFPE) cohort
Baseline characteristics of ORCHESTRA FF cohort and the original FFPE cohort are shown 
in Table 1. There are significant differences in tumor stage (p<0.001), with the ORCHESTRA 
FF cohort including only patients with extrahepatic disease (stage IV) at diagnosis 
versus all stages at diagnosis in our original cohort. In the ORCHESTRA FF cohort, a lower 
percentage of elevated LDH (p<0.001) was observed and baseline tissue biopsies were 
from different locations (metastasis versus primary tumor) (p<0.001). Systemic treatment 
schedules differed significantly for both chemotherapy and the use of bevacizumab and 
response to therapy was significantly different (p=0.03) Table 1. 
Table 1: Comparison of the patient cohort used to compute the initial response prediction 
models (original FFPE cohort) versus the cohort used for this study (ORCHESTRA cohort FF). 
  Prior cohort FFPE ORCHESTRA cohort FF P value
  N=81 N=81  
Gender:   0.870
Female 30 (37.0%) 28 (34.6%)  
Male 51 (63.0%) 53 (65.4%)  
Age at diagnosis (median - range) 61 (37 - 81) 64 (28 - 81) 0.129
Primary tumor location:     
Rectal 20 (24.7%) 34 (42.0%) 0.064
Left sided 30 (37.0%) 22 (27.2%)  
Right sided 31 (38.3%) 25 (30.9%)  
Stage:   <0.001
I 1 (1.20%) 0 (0.00%)  
II 13 (16.0%) 0 (0.00%)  
III 12 (14.8%) 0 (0.00%)  
IV 54 (66.7%) 81 (100%)  
Unknown 1 (1.20%) 0 (0.00%)  
Differentiation:   0.943
Well/ moderately differentiated 54 (66.7%) 54 (66.7%)  
Poorly differentiated 15 (18.5%) 16 (19.8%)  
Other 0 (0.00%) 1 (1.23%)  
Unknown 12 (14.8%) 10 (12.3%)  
Prior adjuvant therapy:   0.072
Yes 7 (8.60%) 16 (19.8%)  
No 74 (91.4%) 65 (80.2%)  
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Liver metastases only:   <0.001
No 57 (70.4%) 81 (100%)  
Yes 24 (29.6%) 0 (0.00%)  
LDH (cut-off 250 ng/µl):    <0.001
Elevated 55 (67.9%) 18 (22.2%)  
Normal 23 (28.4%) 56 (69.1%)  
Unknown 3 (3.70%) 7 (8.64%)  
CEA (cut-off 5 ng/µl):    
Elevated 61 (75.3%) 55 (67.9%) 0.643
Normal 17 (21.0%) 22 (27.2%)  
Unknown 3 (3.70%) 4 (4.94%)  
First line treatment scheme:   <0.001
5-FU monotherapy 14 (17.3%) 0 (0.00%)  
Oxaliplatin-based regimen 57 (70.4%) 81 (100%)  
Irinotecan-based regimen 10 (12.3%) 0 (0.00%)  
Use of first line Bevacizumab:   <0.001
No 51 (63.0%) 21 (25.9%)  
Yes 30 (37.0%) 60 (74.1%)  
Best response to first line treatment:*    
Complete response (CR) 2 (2.5%) 0 (0.00%) 0.025
Partial response (PR) 36 (44.4%) 37 (45.7%)  
Stable disease (SD) 28 (34.6%) 39 (48.1%)  
Progressive disease (PD) 15 (18.5%) 5 (6.17%)  
Tissue specimen:   <0.001
Primary tumor 70 (86.4%) 10 (13.5%)  
Metastasis 11 (13.6%) 64 (86.5%)  
* According to RECIST 1.1. For the original FFPE cohort best response to first line treatment was used 
as clinical endpoint, while for the ORCHESTRA FF cohort response after 3 to 4 cycles of chemotherapy 
was used as clinical endpoint in this table. FFPE: Formalin fixed paraffin embedded, FF: fresh frozen, 
LDH: lactate dehydrogenase, CEA: carcinoembryonic antigen. Data from the original FFPE co hort 
was adapted from Neerincx et al. (15). 
No differences were observed between miRNA expression in stage I – III and IV in the 
original FFPE cohort. All six miRNAs were significantly higher expressed in the ORCHESTRA 
FF cohort compared to the original FFPE cohort ((p=0.03; miR-92a-3p) and p<0.01; other 
miRNAs) (Fig. 4). 
Table 1: Continued
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Figure 4: miRNA expression in the original FFPE cohort compared to the ORCHESTRA FF cohort.
The original FFPE cohort was divided in stage I-III and IV. The ORCHESTRA FF cohort consisted only 
of patients with stage IV disease (IV_O). Differences in expression were compared between stadium 
I-III (n=26) and IV (n=54) from the original FFPE cohort, and between IV (n=54) from the original 
FFPE cohort and IV_O (n=81) from the ORCHESTRA cohort using a 2-tailed unpaired t test. Log2 
expression levels are presented as average from duplicate measurements relative to miR-16-5p. 
miRNA data was adapted from Neerincx et al. (15). NS: not significant.
Discussion
In this prospective study we aimed to validate the predictive value of a previously 
identified miRNA profile combined with clinicopathological factors in predicting early 
response to first line palliative systemic therapy in advanced mCRC (15). The same miRNA 
profile was quantified in serum specimens to test its predictive value as a liquid biomarker. 
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The predictive value of the tissue derived 6 miRNA profile combined with the 
clinicopathological factors could not be validated in patients with mCRC starting with first 
line systemic therapy. Compared to the cohort previously used for identification of the 
putative predictive profile, the clinical parameters of the currently analyzed ORCHESTRA 
FF cohort differed significantly with the most important difference being that this cohort 
consisted of only patients with stage IV disease. Studies have shown that expression levels 
of specific miRNAs differ between clinical tumor stages (37, 38). Though, for miR-17, miR-
20a, miR-30a and miR-92a previous studies have shown no significant relation between 
miRNA expression and stage (20, 39, 40). miR-92b expression has not been related 
to stage before and Zhu et al. found lower levels of miR-98 expression in patients with 
stage III-IV disease compared to patients with stage I-II disease (41). Since there was no 
significant difference in miRNA expression between patients with stage I-III (32%) versus 
stage IV (66.7%) disease in the previous cohort (see table 1), we considered it worthwhile 
testing this signature in a cohort consisting of only patients with stage IV disease, who are 
starting first line palliative systemic therapy.
Additionally, in the original study cohort, patients were treated with different 
chemotherapeutic agents i.e. 5-FU monotherapy, 5-FU with oxaliplatin-based regimens 
or 5-FU with irinotecan-based regimens, which was also an important covariate in the 
prediction model. In the ORCHESTRA FF cohort, all patients received 5-FU with oxaliplatin-
based chemotherapy and therefore this covariate consisted of one factor.
All six miRNAs were significantly higher expressed in the ORCHESTRA FF cohort compared 
to the original FFPE cohort. Besides differences in patient characteristics, this could also 
be the result of methodological differences in RNA extraction and quantification, due to 
updated kits available from Qiagen (after Exiqon merged with Qiagen, the assays from 
Exiqon were updated by Qiagen to exhibit improved performance as stated in digital 
correspondence with Qiagen). In particular, the relatively low expressed miRNAs miR-17-
5p, miR-30a-5p, miR-92b-3p and miR-98-5p were significantly higher expressed in the 
updated assay. 
Furthermore, the biopsy specimens in this cohort consisted of FF tissue, mainly from 
metastatic lesions, whereas in the original FFPE cohort biopsies consisted of FFPE tissue 
samples, mainly from the primary tumor. Although studies have shown good correlations 
between miRNAs quantified in paired FF and FFPE samples independent of the employed 
methodology (5, 42-44), this factor cannot be completely ruled out since an analysis of 
FF versus FFPE of paired samples using similar methods has not been performed for this 
study.
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We previously demonstrated that miRNA profiles of primary tumor and metastases are 
similar, making the biopsy site an unlikely explanation for differences in miRNA expression 
levels (16). The miRNAs selected for this study were based on next generation sequencing 
(NGS) results from FF tissue of 88 patients with advanced CRC as described previously by 
Neerincx et al. (15). The initial clinical endpoint in that study was clinical benefit versus 
progressive disease defined as best response to first line treatment using Response 
Evaluation Criteria in Solid Tumors (RECIST version 1.1) (28). In the study presented here, 
the response was assessed at first evaluation after 3 to 4 cycles of systemic therapy. In 
this cohort, only 5 patients had progressive disease at first evaluation (6.8%). Using other 
evaluation time points (i.e. after 6 to 8 cycles, progression free survival 6 or 9 months) did 
not improve the predictive value either.
miRNA expression by tumor cells may affect serum levels. This depends on the balance 
between the expression levels of tumor cells and the endogenous production of normal 
(circulating blood) cells in the body. High miRNA expression and release by tumor cells 
and low endogenous production are ideal for an optimal predictive biomarker. Here, three 
out of six miRNAs also originate from blood cells (miR-17-5p, miR-92a-3p and miR-20a-5p) 
and therefore have high baseline serum expression levels (31, 45). This was confirmed 
in the current study. Consequently, miRNAs released from tumors may be insufficient 
to significantly alter these high baseline levels. On the contrary, miR-30a-5p, miR-92b-
3p and miR-98-5p were proven to have low baseline serum expression levels, but are 
also expressed at low levels in CRC tissue. Again, these low miRNA levels released from 
tumors might be insufficient to allow detection (with current technology) of alterations in 
baseline serum expression levels. 
Nevertheless, previous studies have identified a predictive and/or prognostic value in CRC 
of serum expression levels of four (miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p) of 
the six miRNAs selected for this study (46-48). Probably other factors, for example the 
composition of the tumor microenvironment, the percentage of immune cell infiltration 
or circulating inflammatory indicators, which are also important factors for therapy 
response, may alter ci-miRNA levels as well. In our dataset the addition of miR-92a-3p and 
miR-98-5p significantly improved the AUC of the ROC curve for predicting response to 
chemotherapy. However, as demonstrated by the wide the range of calculated predicted 
probabilities in Fig. 3B, the predictive value remains moderate and as such not useful in 
clinical practice.
To reduce background noise of endogenous miRNAs in blood cells, miRNAs could be 
quantified in exosomes. It is hypothesized that exosomes released from tumor cells are 
enriched with a tumor specific miRNA signature (49). 
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The predictive models generated from our previous cohort could not be validated in the 
current dataset. In the adjusted models for the ORCHESTRA FF cohort, serum miR-98 and 
miR-92b levels improved response prediction compared to the clinicopathological factors 
alone. The other four miRNAs that were found predictive by others (46-48) were excluded 
from the models because of insignificance and could not be validated in this cohort. 
In conclusion, despite the known role of miRNAs in cancer biology and their favorable 
characteristics to serve as biomarkers, the predictive miRNA signature which was 
previously identified did not show significant strength to predict treatment benefit in 
the present sizeable cohort of patients with mCRC undergoing first line combination 
chemotherapy. This could be partly due to differences in patient population and the 
materials and methods used. It emphasizes the importance of thorough research on 
miRNAs as a predictive marker prior to using it in clinical decision making. Potential 
improvements, by selecting miRNAs in circulating vesicles may provide additional value 
in this matter and requires additional evaluation. 
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Abstract
CD276 can discriminate between tumor derived and normal CECs (circulating endothelial 
cells). We evaluated whether CD276+CEC is a clinically relevant biomarker to predict 
response to palliative systemic therapy in patients with metastatic colorectal cancer 
(mCRC). Samples were prospectively collected from patients with mCRC enrolled in the 
ORCHESTRA trial (NCT01792934). At baseline and after three cycles of 5-fluorouracil/
leucovorin and oxaliplatin ± bevacizumab, CECs were measured by flowcytometry 
(CD34+CD45negCD146+DNA+; and CD276+). A clinically relevant cut-off value of (CD276+)
CECs was determined as 100% sensitivity (and 80% specificity in 95% confidence interval) 
identifying patients with progressive disease within 6 months. There were 182 baseline 
samples and 133 follow up samples available for analysis. CEC and CD276+CEC counts 
significantly increased during treatment from 48 to 90 CEC/4 mL (p = 0.00) and from 14 
to 33 CD276+CEC/4 mL (p = 0.00) at baseline and at first evaluation, respectively. CEC and 
CD276+CEC counts were not predictive for poor response (area under the curve (AUC) 
0.53 for CEC and AUC 0.52 for CD276+CEC). Despite numerical changes during therapy, 
CEC and CD276+CEC counts do not adequately predict poor response to first line palliative 
systemic therapy in patients with mCRC.
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Introduction
Metastatic colorectal cancer (mCRC) is the third cause of cancer related death worldwide 
[1]. Modern palliative systemic therapy regimens consisting of 5FU-based combination 
chemotherapy with oxaliplatin, irinotecan, anti-VEGF targeted therapy, anti-EGFR 
antibodies, and more recently introduced agents (regorafenib, TAS-102) have improved 
overall survival up to a median of 30 months [2–5].
Current first line palliative systemic treatment usually consists of doublet chemotherapy 
with targeted therapy. A triple chemotherapy regimen like FOLFOXIRI with bevacizumab 
has demonstrated high response rates in patients with mCRC [6] and may be a valuable 
option for patients who will not benefit from combination chemotherapy, if these 
patients could be identified upfront. Currently it is recommended that RAS and BRAF 
mutated tumors and right sided primary tumors be excluded from anti-EGFR therapy 
[7,8]. Obviously, there is a clinical need for a biomarker with independent additional value 
that will predict response to first line systemic therapy. If patients who will not respond 
to treatment can be predicted with clinically relevant sensitivity and specificity prior to 
starting systemic therapy, unnecessary treatment can be withheld and toxicity prevented. 
Furthermore, alternative treatment strategies can be considered for these patients.
Circulating endothelial cells (CECs) are cells detached from damaged vasculature. 
Compared to healthy controls, CEC values are frequently elevated in patients with 
disseminated malignancies. Previously, it has been shown that in patients with metastatic 
cancer, CEC numbers at baseline and changes in CEC numbers during systemic therapy are 
associated with prognosis. Consequently, enumeration of CEC is considered a promising 
biomarker in oncology [9]. However, limited data is available on the value of CECs in 
predicting treatment response.
CECs measured in patients with advanced cancer are thought to derive from both 
damaged normal vasculature as well as tumor vasculature. Although CECs have been 
shown to be increased in patients with CRC compared to healthy controls [10,11], this 
surrogate marker of endothelial damage can increase in a variety of conditions including 
ischemia, infections, and vascular or autoimmune disease [12–14]. Measuring tumor-
derived CECs could increase specificity and improve predictive value in cancer. Several 
tumor endothelial markers have been described in literature based on comprehensive 
SAGE (serial analysis of gene expression) analysis and mouse models differentiating 
pathological from physiological angiogenesis [15], with CD276 being a promising 
candidate as described by Mehran et al. and Kraan et al. [16,17]. Tumor cells express 
low levels of CD276, but tumor associated endothelial cells express high levels. In 
mCRC varying results have been published on the relationship of CECs with survival 
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[10,11,13,14,16,18,19]. Direct comparison of the data is difficult because of the use of 
different CEC identification techniques. 
Our group developed a flowcytometry based detection assay for tumor derived 
CD276+CECs, differentiating CECs from non-endothelial cells (i.e., pericytes) and between 
normal and malignant vasculature, which enables to distinguish a subpopulation of CECs 
coming from malignant vasculature in patients with advanced malignancies. CEC counts 
in healthy donors were median 15 (IQR 17.5) [9,17]. Median CD276+CEC counts were 9 
cells/4 mL for patients with advanced CRC (range 1–293, n = 15) compared to 3 cells/4 mL 
for healthy donors. The subset of CD276+CEC in peripheral blood samples were detectable 
above the upper limit of normal (ULN) for healthy individuals (>8 cells/4 mL, mean +1.96 
SD) in more than 53% of patients with advanced CRC (n = 15) [17]. As this subpopulation 
of CD276+CECs and changes therein are likely to reflect better potential effects on tumor 
vasculature than the total number of CECs, further investigation on the frequency of these 
cells and their association with outcome in patients with cancer is warranted.
The primary objective of the current study was to establish the prevalence of CD276+CECs 
in patients with mCRC and evaluating the dynamics of CD276+CECs during systemic 
therapy. Furthermore, we evaluated the association of (CD276+) CEC counts with clinical 
parameters. We aimed to determine a clinically relevant cut-off value of the absolute 
count of CD276+CECs at baseline with 100% sensitivity for patients with progressive 
disease within 6 months of first line palliative systemic therapy, with a specificity of 80% 
included in the confidence interval. 
Materials and Methods
Samples were collected as part of the translational study program of the ORCHESTRA 
trial from May 2013 to July 2018. The ORCHESTRA trial is a randomized multicenter 
clinical trial for patients with multi-organ, colorectal cancer metastases comparing the 
combination of chemotherapy and maximal tumor debulking versus chemotherapy 
alone (NCT01792934).
Written informed consent was obtained from all patients included in the ORCHESTRA 
trial. Patients were 18 years or older and had an indication for first line palliative systemic 
therapy for mCRC. Comprehensive in and exclusion criteria are available at clinicaltrials.
gov. The trial protocol was approved by the Ethical Committee of the VU university Medical 
Center in Amsterdam, the Netherlands (no. 2012-073).
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All patients received 5-FU/oxaliplatin based systemic therapy ± bevacizumab at physician 
discretion. Systemic therapy consisted of orally administered capecitabine 1000 mg/m2 
twice a day for two weeks and oxaliplatin 130 mg/m2 intravenous (CAPOX) on day 1 of each 
3-week cycle or comparable intravenous regimen consisting of oxaliplatin 85 mg/m2 on day 
1 and 400 mg/ m2 LV followed by 400 mg/m2 5-FU bolus and 2400 mg/m2 continuous infusion 
over 46 h (modified FOLFOX6) of each 2-week cycle. Bevacizumab was added at physician 
discretion to the CAPOX regimen at a dose of 7.5 mg/kg bevacizumab as intravenous infusion 
over 30–90 min on day 1. The FOLFOX regimen could be combined with biweekly 5 mg/
kg bevacizumab as intravenous infusion over 30–90 min on day 1. After 3 cycles of CAPOX 
(B) or 4 cycles of FOLFOX (B) a CT scan of thorax and abdomen was performed. Follow up 
scans were done at least every 3 months. Blood samples were collected at baseline and 
at first evaluation (after 3 cycles of CAPOX ± B or 4 cycles of FOLFOX ± B). Samples were 
collected in Cellsave tubes and shipped to central laboratory at Erasmus MC Cancer Institute 
and processed within 96 h. A multi-color flow cytometry protocol was used to identify 
endothelial cells [9]. CECs were defined as nucleated cells staining positively with the DNA 
specific nuclear dye DRAQ5, that express the endothelial markers CD34, CD144, and CD146, 
and lack the expression of the pan-leukocyte marker CD45. By adding CD276 we identified 
the subset of tumor derived CECs. Total and CD276+CEC were enumerated in a total blood 
volume of 4 mL as described previously [17].
Clinical Data 
Data were collected on age, gender, location of primary tumor, location, and number 
of metastases as well as baseline LDH and CEA. Systemic therapy regimen (CAPOX or 
FOLFOX ± bevacizumab) was documented per patient. The number of organs involved 
in metastatic disease, number of metastases and baseline LDH were used as indicators of 
tumor burden. After three cycles of CAPOX (B) or four cycles of FOLFOX (B) response was 
evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST1.1) and at 
least every 3 months thereafter. At data cut off, progression free survival at 6 months after 
study inclusion was documented for all patients.
Statistical Analysis
Median cell counts of (CD276+)CECs and interquartile range were reported. Significance 
levels were calculated with Mann–Whitney U test for dichotomous variables or Kruskal–
Wallis for categorical variables. Baseline and follow-up samples were compared by 
Wilcoxon signed rank test. Areas under the curve were calculated by receiving operating 
curves. Correlations were calculated by Spearman’s Rho. Univariate logistic regression was 
used to calculate predictive value for response.
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Results
Between May 2013 and July 2018 218 patients were included in the ORCHESTRA trial in the 
Netherlands. From 20 patients no baseline sample was available and they were excluded 
from analysis. Sixteen patients did not complete study treatment due to early withdrawal, 
toxicity or death of unknown cause prior to evaluation (Figure 1). This resulted in 182 
patients being evaluable for baseline CEC analysis. From 131 patients, both baseline and 
follow up samples were available. From 30 patients no sufficient follow up was available 
to evaluate response to systemic therapy. Eight patients had progressive disease at first 
evaluation after local treatment as part of the intervention in the ORCHESTRA trial, since 
chemotherapy was therefore interrupted they were excluded from analysis for response 
evaluation. Two patients had evident clinical progression prior to the first per protocol 
evaluation CT scan, both had completed two cycles of systemic therapy and were included 
in this analysis. An overview of the study inclusion is provided in the flow chart (Figure 1).
Patients included in ORCHESTRA
May 2013-July 2018
Baseline CEC sample not availabe n = 20
198
Early drop out  n = 16
1 died prior to evaluation
5 quit systemic therapy due to toxicity
10 early withdrawal unspecified
218
Insufficient follow up  n = 30
Insufficient systemic therapy n = 10
182
142
Figure 1: Flowchart of the inclusion of patients for analyses of CECs.
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(CD276+) CEC Counts
At baseline a median of 48.5 CEC/4 mL (IQR 65) and a median of 18 CD276+CEC/mL (IQR 
35) was measured (Figure 2). The median subset of CD276+CEC from total CECs was 41%. 
We measured a CD276+CEC count higher than the ULN (>8 CECs/4 mL) in 74% of patients. 
CEC counts for relevant clinicopathological variables revealed no significant differences for 
both total CEC and CD276+CEC counts for any of the variables. Total CEC and CD276+CECs 
counts had no significant correlation with white blood cell count, platelets, LDH, CEA, the 
number of organs involved in metastatic disease or total number of metastatic lesions 
(<5, 5–10 or >10). High baseline LDH, involvement of >2 organs or >10 metastases were 
used as surrogate markers for high tumor burden, but did not show significant differences 
in (CD276+)CEC counts (supplementary table). From a subgroup of 40 patients total 
volumetric measurements were done. There was poor correlation with total volume and 
(CD276+)CEC counts (CEC spearmans Rho 0.10, p 0.15, R2 0.003; CD276+CEC Spearman’s 
Rho 0.17, p 0.27, R2 0.006). (data not shown)
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Figure 2: Histograms of (CD276+) CEC counts of all available patients (n = 142).
(A) CEC counts per 4 mL; median 48.5 CEC/4 mL (interquartile range 65). (B) CD276+CEC counts per 
4 mL, median 18 CD276+CEC/mL (interquartile ra ge 35). 
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From 131 patients a follow up sample was available. During systemic therapy the CEC 
count increased significantly (p < 0.00) from median 48 to 90/4 mL. The CD276+CEC 
increased significantly (p < 0.00) from median 14 to 33/4 mL. The CD276+ subset of total 
CECs decreased from 41% to 36% (p = 0.09) (Table 1, Figure 3).































CEC 48 (57) 90 (120) 0.00 * 47 (59) 75.5 (93) 0.00 * 48 (75) 131 (187) 0.03 *
CD276+CEC 14 (33) 33 (50) 0.00 * 15.5 (30) 28 (40) 0.01 * 14 (43) 41 (110) 0.01 *
CD276 subset 0.41 (0.33) 0.36 (0.25) 0.09 0.40 (0.30) 0.35 (0.24) 0.05 * 0.41 (0.36) 0.42 (0.27) 0.74
a BL = baseline. b FU = follow up. c IQR = Interquartile range. * significant p value < 0.05.
(CD276+)CEC dynamics






































Figure 3: CEC and CD276+CEC counts per 4 mL in baseline and follow up blood samples.
* Sig ificant p value
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Baseline (CD276+)CEC values were not significantly different from patients treated with 
or without bevacizumab (Supplementary table; CEC p = 0.80; CD276+CEC p = 0.88). In 
patients treated with bevacizumab, CEC counts were lower after three cycles compared 
to patients treated with chemotherapy alone 75.5 vs. 131 CEC/4 mL (p = 0.04), 28 vs. 41 
CD276+CEC/4 mL (p =0.08). Both in patients treated with doublet chemotherapy alone 
and patients treated with chemotherapy and bevacizumab a significant increase in total 
CEC and CD276+CEC counts was seen after three cycles of systemic therapy. 
For patients treated with doublet chemotherapy plus bevacizumab (N = 98) there was a 
significant increase in total CEC counts after three cycles of systemic therapy (from median 
47 to 75.5/4 mL, p = 0.00), and CD276+CEC from median 15.5 to 28/4 mL (p = 0.01). The 
CD276+ subset of total CECs decreased significantly after treatment from 40% to 35% in 
the follow up sample (p = 0.05). 
For patients treated with only doublet chemotherapy without bevacizumab (N = 33) both 
total CEC as well as CD276+CEC counts increased significantly after three cycles of therapy 
(median CEC from 48 to 131; p = 0.03 and median CD276+CEC from 14 to 41 p = 0.01). The 
subset was 41 versus 42% respectively (p 0.74) (Table 1). 
None of the circulating endothelial cell measurements, both baseline or follow up CEC and 
CD276+CEC counts, nor the change in CEC count (Delta CD276+CEC) could predict poor 
response to systemic therapy with statistical significance (Table 2). Receiver operating 
characteristic (ROC) curves for total CEC and CD276+CEC in predicting progressive disease 
within 6 months showed low AUCs of 0.533 for total CEC and 0.524 for CD276+CEC (Figure 4). 
Table 2: Response prediction of (CD276+)CEC
PFS a > 6 Months
Median (IQR b)




Baseline CEC 48 (67) 48 (67) 0.60
Baseline CD276+CEC 18 (35) 17 (29) 0.70
Subset 0.43 (0.34) 0.37 (0.36) 0.87
n 89 17
FU d CEC 76 (131) 131 (98) 0.14
FU d CD276+CEC 25 (51) 42(34) 0.13
FU d subset 0.36 (0.26) 0.36 (0.28) 0.78
Delta CEC 14 (91.5) 87 (114.5) 0.08
Delta CD276+CEC 7 (37) 22 (49) 0.08
a PFS = Progression Free Survival. b IQR= Interquartile range. c MWU = Mann-Whitney-U test. d FU = 
follow up.
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(a) Baseline CEC correlation with progression free survival (Long versus Short); Area under curve (AUC) = 0.533. 











(a) Baseline CEC correlation with progression free survival (long versus short); Area under curve 
(AUC) = 0.533. (b) Baseline CD276+CEC correlation with progression free survival (long versus short); 
AUC = 0.524.
Discussion
Our study was designed to evaluate the prevalence of tumor derived circulating 
endothelial cells (CD276+CEC) measured by flowcytometry in patients with mCRC and 
explore the predictive value for response to systemic therapy. Previous studies evaluating 
CEC using (CD34+CD45negDNA+CD146+) for CEC identification focused mainly on 
predicting survival in patients treated with first line systemic therapy for mCRC [18,19]. 
Both studies used the CellSearch system (by Veridex®, Menarini Silicon Biosystems Inc. 
Huntington Valley, PA 19006, one showing no prognostic value for PFS or OS [18], the 
other increase of PFS and OS for baseline CEC counts < 65/mL [19]. In a third prospective 
series, CEC ≤ 21/4 mL was found to be an independent prognostic factor of poor survival 
for patients with mCRC amenable for potentially curative surgery, which was of stronger 
prognostic value than circulating tumor cells [20]. The flow cytometry enumeration we 
used, as described before by Kraan et al. has the same markers for CEC identification, 
albeit with different fluorescent antibodies. CEC counts demonstrated to correlate well 
with CellSearch system counts, with a slightly higher recovery [9]. Other studies used flow 
cytometry for CEC enumeration with different cluster of differentiation markers. Ronzoni 
et al. [10], showed increase of PFS and OS for patients with mCRC with CEC count < 40/
mL (CD45neg CD146+CD34+CD133neg) if treated with first line palliative systemic therapy 
with bevacizumab. Malka et al. [14] showed increase in PFS but not for OS (cut off 23 
CEC/mL based on CD31+CD146+CD45neg7AADneg viable cells/mL by FACS analysis) in 97 
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patients from the randomized phase II FNCLCC ACCORD 13/0503 trial, receiving first line 
palliative systemic therapy with bevacizumab with either XELIRI or FOLFIRI. In patients 
undergoing resection for colorectal liver metastases CEC counts (CD34+CD45negCD146+) 
before surgery did not have additional value in predicting 2 year outcome [21]. 
We were able to detect CECs by FACS analysis in all patients with a range from 2–1627 
per 4 mL blood and CD276+CECs were measured in all but one patient, ranging from 
0–1608/4 mL. The median CEC count of 48.5/4 mL (12/mL) is higher than reported by 
others using the same markers. Simkens et al. reported a median of 6.8 CEC/mL in a large 
population of 435 patients [18]. Studies from CEC counts prior to liver resections reported 
5/mL (CellSearch, 140 patients) or 10 vs. 20/mL for patients with respectively good (N = 
102) or poor (N = 52) outcome, (CD34+CD45−CD146+ measured by FACS). [20,21]. In this 
study, a significant higher CEC count after three cycles of chemotherapy (p = 0.00), with 
a nearly 2-fold increase (48 to 90/4 mL) was detected. This is in line with the findings of 
Simkens who reported a 1.5 fold increase (median CEC from 6.8 to 10.5/mL after 6–12 
weeks), which was not prognostic for PFS or OS [18].
Our aim was to identify patients who progress within 6 months of start with therapy by 
(CD276+)CEC counts. The AUC of the ROC for CEC counts duration of response < 6 months 
was 0.53 and 0.52 for CD276+CEC counts, indicating that measuring (CD276+)CECs is a 
poor test to predict response to therapy. No clinically relevant cut-off value could be 
established. Baseline (CD276+)CEC counts were not significantly different for any baseline 
clinicopathological variable. We were not able to validate the cut-off established by 
Malka et al. [14] who found baseline CEC above the 75th percentile to be an independent 
prognostic factor for 6 months PFS rate (p = 0.44,), nor the finding by matsusaka et al. [19] 
who found an increase of pFS and OS for patients with a baseline CEC count of <65/mL 
(p 0.347).
There are several potential factors that might confound our results. CD276 could also 
be detected in normal liver endothelium [16]. As in our cohort 83% of patients had liver 
involvement in metastatic disease, this could interfere with tumor specificity of the 
CD276+CECs, due to CD276 expression on liver endothelial cells. In contrast with this 
thought, we did not find a significant difference between CD276+CEC counts of patients 
with or without liver metastases (median 17 vs. 23/4 mL; p = 0.33, data not shown). 
Since patients had to had adequate liver function to be eligible for study participation, 
important underlying liver disease interfering with CD276+CEC counts seems unlikely. 
Only 5% of patients had > grade 1 elevation of liver enzymes at follow up, possibly 
reflecting oxaliplatin induced liver toxicity, no important changes in CD276+CEC counts 
were seen in these patients.
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Since circulating endothelial cells act as a surrogate marker of endothelial damage, counts 
can increase in a variety of conditions including ischemia, infections, and vascular or 
autoimmune disease. All baseline samples were taken prior to start of systemic therapy. 
Previous adjuvant systemic therapy did not include bevacizumab and was at least 6 
months prior to inclusion and is therefore less likely to influence measurements. 
Prior to trial participation, patients with hypertension should have well controlled 
blood pressure under 160/95 mmHg on a stable antihypertensive regimen (grade II 
hypertension according to CTCAE 4.03). Patients with uncontrolled infections, a history 
of congestive heart failure >New York Heart Association class 2 or active coronary artery 
disease and cardiac arrhythmias requiring anti-arrhythmic therapy were excluded from 
trial participation (beta blockers or digoxin permitted). Closer evaluation of six patients 
with baseline (CD276+)CEC values > mean +2 SD, revealed no hypertension or a history 
of peripheral vascular or cerebrovascular disease in these patients. None of these patients 
had surgery or radiotherapy < 6 weeks prior to baseline measurement.
Patients were not randomized to receive bevacizumab or not. Seventy-six percent of 
patients were treated with bevacizumab in combination with CAPOX or FOLFOX at 
physician discretion, which is in line with guidelines adherence in the Netherlands (63–71% 
use of targeted therapy in first-line treatment) [22]. The reason to withhold bevacizumab 
was in 42% a (relative) contraindication for anti-VEGF therapy and for 32% due to the fact 
that bevacizumab administration was no standard practice in the institution. We did not 
find significant differences in baseline CEC and CD276+CEC counts between patients that 
did or did not receive bevacizumab. 
Kinetics of CECs have been studied with varying results. Murine models showed that 
VEGF pathway inhibitors can have differential effects on CECs in that inhibition of 
tumor angiogenesis is associated with an initial increase in mature CECs, followed by 
a subsequent reduction [16]. We showed a significant increase in CEC and CD276+CEC 
counts during treatment with chemotherapy combined with bevacizumab. The subset of 
CD276+CEC decreased from 40% to 35% (p = 0.05). Simkens found an significant increase 
after 1–2 weeks compared to baseline in patients with mCRC, with no further increase 
thereafter [18]. Ronzoni et al. [10] did not find a significant change in CEC counts (CD45−
CD146+CD34+CD133neg by FACS) for patients with radiologic response. Manzoni et al. 
[11] showed that patients with an increase in CECs (CD45negCD146+D34+, CD133neg by 
FACS) at the sixth cycle of first line chemotherapy in combination with bevacizumab had 
a better PFS (p 0.009). 
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Conclusions
In conclusion, CD276+CEC counts can be measured in patients with mCRC, but no 
correlation with clinical parameters was demonstrated. Cell counts increased during 
systemic therapy. In patients treated with bevacizumab, CEC and CD276+CEC counts 
in follow up samples were lower compared to patients not treated with bevacizumab. 
Despite numerical changes during therapy, (CD276+)CEC counts alone do not adequately 
predict poor response to first line palliative systemic therapy in patients with mCRC. 
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Supplementary Materials












Male 118 (66) 48 (59) 17 (35)
Female 61 (34) 50 (70) 19 (48)
Age 0.97 0.75
<65 97 (54) 52 (66) 20 (45)
≥65 82 (46) 47.5 (69) 15 (31)
Chronicity 0.92 0.57
Synchronous 108 (60) 46.5 (78) 17.5 (31)
Metachronous 72 (40) 51 (51) 17.5 (40)
Sidedness of primary 
tumour
0.86 0.71
Left 129 (70) 48 (62) 17 (29)
Right 52 (30) 53.5 (69) 21 (51)
Tumour location 0.87 0.55
Colon 101 (56) 53 (75) 20 (49)
Rectum 80 (44) 47.5 (54) 17.5 (24)
Primary in situ 0.94 0.71
Yes 66 (36) 49 (66) 21.5 (35)
No 116 (64) 48.5 (64) 16 (41)
Number of  
metastases
0.78 0.75
<5 39 (22) 56 (64) 22 (53)
5-10 88 (49) 47.5 (67) 18 (40)
>10 or diffuse 51 (29) 48 (71) 14 (35)
Number of organs 
involved
0.58 0.44
2 107 (59) 52 (77) 21 (44)
>2 75 (41) 48 (54) 14 (24)
CEA ug/l 0.90 0.67
>5 135 (78) 50 (67) 18 (36)
<5 38 (22) 44 (55) 17 (37)
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Chemotherapy2 0.23 0.44
CAPOX 171 (94) 50 (68) 19 (42)
FOLFOX 10 (6) 33.5 (28) 12.5 (13)
Bevacizumab
Yes 138 (76) 49.5 (68) 0.90 18 (35) 0.82
No 43 (24) 45 (53) 14 (42)
Prior (neo) adjuvant 
chemo
0.44 0.23
Yes 34 (19) 44 (52) 13 (26)
No 147 (81) 50 (68) 18 (41)
Prior chemoradiation 0.41 0.55
Yes 31 55 (50) 25 (21)
No 150 46.5 (70) 17.5 (45)
Response at first 
evaluation
0.41 0.81
PD3 11 35 (192) 0.41 13 (79) 0.81
Non PD3 158 48 (66) 17.5 (35)
LDH 0.50 0.38
Normal 144 (81) 48 (69) 18 (35)




Yes 59 (33) 50 (81) 23 (44)
No 121 (67) 48 (58) 17 (35)
ECOG PS4 0.55 0.39
0 115 (73) 48 (58) 18 (33)
1 43 (27) 48 (70) 22 (42)
1 IQR = Interquartile range
2  CAPOX = combination chemotherapy with capecitabine and oxaliplatin. FOLFOX = combination 
chemotherapy infusional 5-FU/Leucovorin and oxaliplatin.
3 PD = progressive disease
4 Eastern Cooperative Oncology Group Performance Scale
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Abstract 
Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) 
are used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of 
patients benefit despite patient selection for RAS wild type (wt) tumors. Based on the 
hypothesis  that tumor targeting is required for clinical benefit of anti-EGFR treatment, 
biodistribution and tumor uptake of 89Zr-cetuximab by Positron Emission Tomography 
(PET), combining the sensitivity of PET with the specificity of cetuximab for EGFR was 
evaluated. Ten patients with wt K-RAS mCRC received 37±1 MBq 89Zr-cetuximab directly 
(< 2h) after the first therapeutic dose of cetuximab. PET-scans were performed from 1 
hour to 10 days post injection (p.i.). Biodistribution was determined for blood and organs. 
Uptake in tumor lesions was quantified by Standardized Uptake Value (SUV) and related to 
response. In 6 of 10 patients 89Zr-cetuximab uptake in tumor lesions was detected. Four of 
6 patients with 89Zr-cetuximab uptake had clinical benefit, while progressive disease was 
observed in 3 of 4 patients without 89Zr-cetuximab uptake. Taken together,  tumor uptake 
of 89Zr-cetuximab can be visualized by PET imaging. The strong relation between uptake 
and response warrants further clinical validation as an innovative selection method for 
cetuximab treatment in patients with wt RAS mCRC.
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Introduction
Systemic treatment for patients with RAS wild type (wt) colorectal cancer (mCRC) 
includes anti– epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) 
treatment with either cetuximab or panitumumab as monotherapy or in combination 
with chemotherapy [1]. Binding of anti-EGFR mAb prevents ligand binding to its receptor, 
induces receptor internalization and causes inhibition of the receptor tyrosine kinase 
activity, thereby interfering with cell growth, differentiation, proliferation, apoptosis and 
cellular invasiveness [2]. Selection of patients who will benefit from this therapy remains an 
area of ongoing research. Patients with mCRC harboring a K-RAS mutation [3-5] or N-RAS 
mutation [6] do not respond to anti-EGFR treatment. However, despite selection based on 
mutational status, clinical benefit (complete or partial resonse and stable disease according 
to RECIST 1.1) to single agent cetuximab is observed in approximately half of the patients 
with wt RAS mCRC [6].  Additional mutations (such as BRAF) may play a role, but have 
not proven to be definitive biomarkers for response [7]. Variability in pharmacokinetics 
of the antibody may also play a role in its clinical efficacy. It can be influenced by the 
expression level of the antigen throughout the body in addition to the expression level in 
tumor lesions. EGFR is highly expressed on hepatocytes, possibly leading to sequestration 
of anti-EGFR mAbs in normal liver tissue. This may result in insufficient circulating anti-
EGFR mAbs to reach tumor lesions, prohibiting antitumor activity. Cetuximab through 
levels correlate with progression free survival, supporting the hypothesis that cetuximab 
availability is crucial for its antitumor activity [8]. The observation that increased skin 
toxicity is associated with a favorable response might also be explained by higher levels 
of circulating mAb. Indeed, dose escalation based on the level of skin toxicity showed a 
possible avenue for improved efficacy [9]. 
We hypothesize that response to treatment is dependent on uptake of cetuximab in 
tumor lesions. Differences in biodistribution and tumor uptake of the antibody can be 
evaluated by immunoPET imaging as demonstrated by successful proof-of-principle 
studies in humans [10, 11]. The half life of the radiotracer 89Zr (t1/2 = 78.4 h) matches the 
biological half-life of intact antibodies with slow kinetics like cetuximab. In a preclinical 
study with tumor-bearing mice, 89Zr-cetuximab uptake was demonstrated in EGFR-
positive tumors. 89Zr-cetuximab uptake did not correlate with EGFR expression levels, 
implying that pharmacokinetic and pharmacodynamic factors might influence cetuximab 
accumulation in the tumor [12]. 
We performed 89Zr-cetuximab PET imaging in patients with wt K-RAS mCRC with an 
indication for anti-EGFR mAb monotherapy to investigate biodistribution and tumor 
uptake as well as to establish the optimal scanning time point to visualize tumor targeting. 
Most importantly, we evaluated whether uptake on 89Zr-cetuximab PET imaging can 
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discriminate between patients responding to treatment with cetuximab versus non-
responding patients.
Results
Ten patients with wt K-RAS mCRC and an indication for cetuximab monotherapy were 
enrolled. A table with patient characteristics is shown in the supplementary materials 
(Sup 3). No 89Zr-cetuximab related toxicity was reported. Only known adverse events to 
cetuximab were observed, such as skin toxicity, hypomagnesaemia and infusion related 
reactions, none exceeding grade 2. 
Whole body (WB) images, acquired at consecutive time points after administration 
of 89Zr-cetuximab (Figure 1 Timeline), showed radioactivity in blood pool, liver, kidney, 
spleen, intestine and bone marrow. We observed no visible uptake in the skin (Figure 2). 
The % injected dose (ID) (decay corrected) in spleen, kidneys and lungs as well as blood 
pool decreased in time. In liver, the %ID increased during the first two days, after which 
uptake plateaued at approximately 23% of ID (SD 4%) (Figure 3), with a marked increase in 
organ to blood pool ratio. Radioactivity concentration as measured in the blood samples 
correlated well with the image derived input (R² = 0.97; Sup 2). At day 6 p.i. the total 
radioactivity retrieved from the WB PET images had decreased by 18.5% compared to the 
first scan due to gastrointestinal excretion, as no excretion via the bladder was observed. 
Figure 1: Timeline.
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Figure 2: Uptake of 89Zr-cetuximab in patient 3 with tumor lesions in the pelvis and sacral bone. 
Presented images are with equal SUV max (decay corrected). Visual inspection shows uptake in 
normal organs which is decreasing over time. 89Zr-cetuximab is sequestered in liver, a relatively 
photopenic lesion is observed at the site of a liver metastasis (arrow). Accumulation of 89Zr-
cetuximab over time is demonstrated in the tumor lesions. On the last scan a rectal hotspot with 
excreted 89Zr in feces is seen. Due to positioning of the patient in the scanner the head and neck 
region is not visible in this plane.
Figure 3: Biodistribution (%ID) of 89Zr-cetuximab as a function of time (days p.i.) for kidney, 
liver, lung, spleen and whole blood. 
Data are image derived and decay corrected. Error bars denote the standard deviation. (n=7)
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In 6 out of 10 patients, target lesions were visually assessed positive for 89Zr-cetuximab 
uptake. Figures 4A and 4B show examples of visible 89Zr uptake in a metastatic lesion of the 
iliac bone (patient 8) and the lung (patient 10). In figure 4C, another lung lesion in patient 
10 shows no uptake. Most tumor lesions showed increasing uptake in time, indicating 
accumulation of cetuximab. SUVpeak of these lesions varied between 2.2 - 7.5 on day 6 p.i.. 
Figure 4D illustrates the photopenic aspect of liver metastases within normal liver tissue 
accumulating high amounts of 89Zr-cetuximab. Two of the 3 patients who were scanned 
at day 10 p.i. had visible 89Zr-cetuximab uptake. SUVpeak at day 10 increased compared to 
day 6 in patient 8 (from 7.3 to 10.3), but was comparable in patient 6 (3.17 and 3.36, Figure 
4 E Due to the physical half-life of 89Zr, image quality deteriorated over time, making day 
6 p.i. the optimal scanning time point. Visually negative tumor sites had SUVmean of 1.0-1.9 
at day 6 p.i. (Figure 5).
Figure 4A: 89Zr-cetuximab PET scan of patient 8 at day 6 p.i. with visible uptake in tumor 
lesion in the left iliac bone.
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Figure 4B: 89Zr-cetuximab PET scan of patient 10 at day 6 p.i. with visible uptake in tumor 
lesion in the lower lobe of the right lung and low accumulation in surrounding healthy lung 
tissue.
Figure 4C: 89Zr-cetuximab PET scan of patient 10 at day 6 p.i. without visible uptake in tumor 
lesion in the upper lobe of the right lung.
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Figure 4D: 89Zr-cetuximab PET scan of patient 3 at day 6 p.i. illustrating high 
















P3 - sacral bone
P6 - lung 1
P6 - lung 2
P8 - iliac bone
P9 - lung
P9 - lymph node
P10 - lung 1
Figure 4E: SUVpeak calculated for tumor lesions with visible 
89Zr-cetuximab uptake at 
sequential scanning time points.
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Figure 5: Average SUVpeak of target lesions on day 6 p.i. Filled bars represent patients with 
visible 89Zr-cetuximab uptake, dashed bars represent lesions with no visible uptake. 
Patient ID based on chronological order of inclusion.
The majority of patients had 2 evaluable lesions and in all but one patient, 89Zr-cetuximab 
tumor uptake was either present or absent in both lesions. Five patients had stable 
disease according to RECIST 1.1. Of 6 patients with visible tumor uptake of 89Zr-cetuximab, 
4 experienced meaningful clinical benefit. Three of 4 patients without visible uptake had 
progressive disease at first evaluation at 8 weeks after start of treatment (Table 1).
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Table 1: 89Zr-cetuximab uptake in extrahepatic target lesions.







3 Pelvic bone +
+
Sacral bone +
4 Adrenal gland -
+
Soft tissue -
5 Adrenal gland -
-
Lymph node -
6 Lung (1) +
-
Lung (2) +
7 Primary tumor - -
8 Iliac bone + +







We evaluated 89Zr-cetuximab PET imaging in patients with wt K-RAS mCRC and found 
tumor uptake of 89Zr-cetuximab in 6 out of 10 patients of whom 4 had clinical benefit 
of cetuximab treatment (Table 1). Based on the design of this clinical trial in which we 
expected uptake in ≥1 of 10 or ≤ 7 of 10 patients (power >90%, type I error <5%), our 
results indicate that tumor uptake of 89Zr-cetuximab may be used to predict clinical 
benefit of cetuximab in patients with wt K-RAS mCRC, which should be further validated 
in a larger cohort of patients.
 
Previously, a dosimetry study of 99mTc-C225 (= cetuximab) in patients with squamous cell 
carcinoma of the head and neck showed reasonable dosimetric properties, however, 
tumor uptake was not evaluated in this trial [13]. 
In order to optimally reflect the biodistribution of the mAb in patients, immediate binding 
of the labeled mAb to easy accessible non tumor sites, e.g. liver, should be minimized. A 
study evaluating 111In-C225 in patients with squamous cell lung carcinoma showed that 
liver sequestration of 111In -C225 decreased from 32 to 21.6 %ID with increasing dose 
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of unlabeled C225 (up to 300 mg). Furthermore, increasing doses of unlabeled C225 
resulted in higher tumor uptake of 111In-C225 [14]. Similar results were obtained with 
89Zr-trastuzumab directed against HER2. In trastuzumab-naive patients administration 
of only 10 mg unlabeled trastuzumab resulted in a relatively high uptake in the liver, 
whereas imaging characteristics were optimal when 50 mg unlabeled trastuzumab was 
administered [11].
As a proof of principle, we administered a scouting dose of 0,1 mg 89Zr-cetuximab before 
the unlabeled therapeutic dose of cetuximab in three patients. In blood samples taken 2 
and 3 hours after administration of the scouting dose,  only <10 %ID 89Zr-cetuximab could 
be detected. However, by administration of the therapeutic dose of 500 mg/m2 cetuximab 
before the labeled fraction, sufficient 89Zr-cetuximab was found in the blood pool for tumor 
targeting (80% ID, see Fig 2). In addition, the half life  of 89Zr-cetuximab if co-administered 
with the therapeutic dose, is comparable to unlabeled cetuximab, indicating that in our 
model 89Zr-cetuximab reflects biodistribution of unlabeled cetuximab. 
Tumor uptake was initially evaluated by visual assessment, which implies contrast with 
background activity. The optimal scanning time point appears to be day 6 p.i., which is 
in line with literature and our expectations, based on the t½ of 
89Zr [10]. The subsequently 
calculated SUVpeak at day 6 p.i. can discriminate between lesions with and without visible 
uptake (Figure 5) and suggests that a cut-off SUVpeak could be helpful in the determination 
of specific uptake versus background activity. Because a significant amount of the ID of 
89Zr-cetuximab accumulated in the liver, hepatic metastases – although large enough 
for imaging purposes (diameter 4 – 14 cm) - were unsuitable to evaluate tumor uptake 
as spill-over from uptake in adjacent normal liver tissue hampered adequate uptake 
evaluation of tumor sites. In addition, many large lesions have central necrosis with only 
a rim of viable tumor tissue, which is located immediately adjacent to healthy liver tissue 
accumulating very high levels of 89Zr cetuximab. As liver is a common metastatic site of 
mCRC, we have attempted to quantify uptake in hepatic metastases. In 6 target lesions 
in 5 patients we observed transient accumulation of 89Zr-cetuximab with highest levels 
at day 2 pi showing a comparable pattern as healthy liver tissue (data not shown). As 
the uptake pattern largely followed normal liver tissue, quantification of hepatic lesions 
seems to be unreliable due to spill-over of adjacent liver tissue. With the liver being a 
common metastatic site of mCRC this can limit the use of 89Zr-cetuximab as a treatment 
selection tool.
The data in this study are too limited to draw conclusions on the correlation between 
blood concentration, liver uptake, tumor targeting and response. However, three patients 
who did not show uptake had progressive disease at first response evaluation. One could 
postulate that insufficient cetuximab was available for uptake in tumor lesions due to 
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sequestration in the liver or other EGFR expressing organs. For example, one patient who 
had no visible 89Zr-cetuximab uptake in target tumor lesions, had rather high liver uptake 
(29.0 %ID, average all patients 22.8 ± 3.5 %ID) and relatively low plasma levels at day 6 p.i. 
(10.0 %ID, average all patients 18.1 ± 6.5  %ID) suggesting possible inadequate availability 
in tumor tissue. 
Of 6 patients showing 89Zr-cetuximab uptake, 4 had clinical benefit. When comparing 
patient 6, 9 and 10 who all had lung metastases showing uptake, only patient 9 and 10 had 
clinical benefit. The lack thereof for patient 6 may be due to the multiple lines of previous 
therapy including radiotherapy on the lung metastases compared to 1-2 previous lines of 
therapy for the other two patients leading to a potential difference in tissue architecture 
and cellular content of these lesions. The absence of response may also be due to N-RAS 
or other mutations, however, unfortunately no adequate tumor material was available 
for further assessment of the mutational status in these patients. One patient had clinical 
benefit, although 89Zr-cetuximab uptake could not be visualized. Possibly, the amount of 
cetuximab that reached the tumor was insufficient for visual assessment, but did induce 
anti-tumor activity, for example by antibody-dependent cell-mediated cytotoxicity 
[15]. For 7 patients with two lesions available for quantification only patient 10 showed 
heterogeneous uptake of 89Zr-cetuximab (Figure 4B and 4C). Although all lesions in this 
patient showed response to treatment, one of the lung lesion did not show visible uptake 
of 89Zr cetuximab. This might be caused by a difference in size, the negative lesion is 
smaller compared to the others and thereby relatively unfavorable for 89Zr PET imaging.
In conclusion, PET-imaging with 89Zr-cetuximab is feasible. Despite relatively high liver 
uptake, variable tumor uptake can be demonstrated in extra-hepatic metastases of 
patients with wt K-RAS colorectal carcinoma by visual assessment of 89Zr-cetuximab PET 
scans. The optimal scanning time point appears to be at day 6 post radiotracer injection. 
With 6 of 10 patients showing uptake, statistical conditions were met for 89Zr-cetuximab 
imaging to qualify as a potential treatment selection tool, however additional data are 
needed to confirm this 
We are currently investigating whether tumor uptake on 89Zr-cetuximab PET scan could 
guide dose escalation to improve the clinical response (NCT02117466). Ultimately, we 
aim to develop a PET-imaging guided tool to select patients who could benefit from 
cetuximab treatment.
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Material and methods
Patients
Patients with histologically proven exon 2 K-RAS wt mCRC, were eligible if they had 
progressive disease after standard first and second line treatment (fluoropyrimidines, 
oxaliplatin and irinotecan) or had contra-indications to these agents. Only K-RAS  exon 
2 mutations were tested prior to inclusion because the trial was started prior to the 
publication on the importance of other K-RAS or N-RAS mutations [6]. Eligible patients 
had ECOG of 0-2, a life expectancy of at least 12 weeks, good end-organ function, and 
one or more measureable lesion outside the liver according to RECIST 1.1. Prior anti-EGFR 
therapy as well as skin conditions interfering with EGFR inhibition were exclusion criteria 
amongst others. The study (NCT01691391) was reviewed and approved by the Central 
Committee on Research Involving Human Subjects of the Netherlands and the Medical 
Research Ethics Committee of the VU University Medical Center, the Netherlands. All 
patients gave written informed consent prior to any study specific procedures. 
89Zr-cetuximab 
89Zr has been produced and purified as described before and is coupled to mAbs via the 
bifunctional chelate desferal (Df ), [16, 17] which has been safely used in the clinic before 
[10]. 89Zr-cetuximab is produced in compliance with current Good Manufacturing Practice 
at the VU University Medical Center. The procedures for radiolabeling of cetuximab with 
89Zr have been validated with respect to the final quality of the prepared conjugate. Details 
can be found in supplementary material (Sup 1). 
Treatment with cetuximab
Patients were treated with 500 mg/m2 cetuximab administered intravenously every 
two weeks. Adverse events were graded according to CTCAE v4. Tumor response was 
analyzed every 8 weeks according to RECIST 1.1 (Figure 1). Treatment was ended in case 
of unacceptable adverse events, worsening symptoms of disease, clinical or radiological 
disease progression, request by the patient or death.
89Zr-cetuximab PET
Within 2 hours after the first administration of 500 mg/m2 unlabeled cetuximab, 10 mg of 
89Zr-cetuximab (37 ± 1 MBq) was injected. The injected dose 89Zr (MBq) was corrected for 
residual activity in the syringe and needle. Whole-body (WB) PET scans (mid-femur-skull 
vertex) were acquired 1-2 hours and 1, 2, 3 and 6 days post injection (p.i.) in 7 patients 
and 6 and 10 days p.i. in 3 patients (Figure 1). At every scanning time point, venous blood 
samples were taken for pharmacokinetic purposes. A 35 mAs low-dose (LD) CT scan was 
acquired for attenuation correction and localization purposes. PET scans consisted of 10-
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12 bed positions, of 5 min each. PET data were corrected for dead time, scatter, randoms, 
decay, and tissue attenuation and reconstructed according to Makris et al [18]. 
An [18F]-FDG PET/CT was performed at baseline to identify target lesions. 89Zr-cetuximab 
PET images were visually assessed for 89Zr-cetuximab uptake in target lesions. Images 
were evaluated by a nuclear medicine physician (OSH) and a medical oncologist (CWM). 
During the first reading session the nuclear medicine physician was blinded for clinical 
information on target lesion distribution. Tumors were scored as either positive or 
negative for 89Zr-cetuximab uptake by consensus, as a function of tracer uptake versus 
direct background. 
Quantification of uptake
For quantification of radiotracer accumulation in organs, regions of interest (ROI) were 
drawn manually on the 89Zr-cetuximab PET images or the co-registered LD CT scan if 
organ delineation was unclear on PET. Average activity concentration (AC) was measured 
and percentage of injected dose (%ID) was calculated. Image derived AC in the blood 
pool was calculated from fixed-size ROI (total volume ~1.6 mL) placed in the middle of the 
aortic arch on LD CT, on 5 consecutive planes. AC was measured and %ID was calculated 
based on estimated blood volume.
Radiotracer accumulation in tumors was calculated by drawing ROIs on the PET images 
and Standardized Uptake Value (SUV) corrected for body weight was calculated from the 
measured AC. In tumors with visible uptake, SUVpeak was calculated [18, 19]. For tumor 
lesions without visible uptake, an average background activity was measured in a 5 cm 
diameter ROI in the area of the tumor lesion and SUVmean was calculated. WB ROIs were 
drawn to calculate the total activity measured in the acquired PET images. Total activity 
measured on day 6 p.i. was compared to the activity at 1 hr p.i. to evaluate excretion of 
89Zr-cetuximab. AC was corrected for decay between the time of injection and the start 
time of the scan.
Statistics
Based on the clinical benefit rate of single agent therapy with cetuximab in wt K-RAS 
patients and the assumption that uptake is related to response, we hypothesized that 
40% of patients would show 89Zr-cetuximab uptake in tumor lesions [3-5]. If this is correct, 
we expected uptake in ≥1 of 10 or ≤ 7 of 10 patients (power >90%, type I error <5%).
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Supplementary Materials
Sup 1: 89Zr-Cetuximab labelling procedure
89Zr has been produced and purified as described before and is coupled to mAbs via the bifunctional 
chelate desferal (Df ),13 which has been safely used in the clinic before.10 In the conjugation of 
cetuximab with desferal 3 equivalents of chelator have been used. On average 1.5 desferal groups 
are coupled per antibody molecule as determined by SEC-HPLC at 430 nm. In the radiolabeling ~ 2.5 
mg DFO-cetuximab is used. After radiolabeling and taking the right amount of Zr-89 this is brought 
up to 10 mg with cold cetuximab. 
 89Zr-cetuximab is produced in compliance to current Good Manufacturing Practice at the VU 
University Medical Center. The procedures for radiolabeling of cetuximab with 89Zr have been 
validated with respect to the final quality of the prepared conjugate. The mean labeling efficiency 
was 85.4 ± 3.7%. The mean percentage of label bound to the antibody as assessed by TLC was 97.9 
± 0.9%, while the mean immunoreactive fraction as assessed by cell binding assay16 was 95.4 ± 3%. 
Sterility of each 89Zr-cetuximab batch was assured by performing a media fill immediately after final 
filter sterilization of each batch. These procedures resulted in a sterile final product with endotoxin 
levels < 2.5 EU/mL.
Sup 2: Figure
Correlation of whole blood measured and image derived blood Activity Concentrations (AC) in Bq/
ml.
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  1st line 2nd line
1 F 66 colon pleura, lung, subcutaneous folfox irinotecan  
2 M 73 sigmoid lymph node, liver, lung   capox-b irinotecan
3 M 54 rectum lymph node, liver, sacral bone, 
pelvic bone
  capox-b folfiri
4 M 72 Sigmoid, local 
recurrence
liver, adrenal gland ,tumor 
deposit
  capox-b irinotecan
5 M 61 coecum lymph nodes, adrenal gland, 
peritoneal deposit
  folfox irinotecan
6 F 66 rectum lymp nodes, lung capox capox-b capiri
7 M 52 sigmoid lymph nodes, liver   capox-b folfiri
8 M 58 rectum iliac bone   capox irinotecan
9 F 50 rectum liver, lung, lymph nodes   capox-b  
10 F 54 sigmoid lung, liver   folfox irinotecan
capox: capecitabin and oxaliplatin, capox-b: capox and bevacizumab, folfox: 5FU/LV and oxapliplatin, 
folfiri: 5FU/LV and irinotecan, capiri: capecitabin and irinotecan.
CHAPTER 7
Summarizing discussion and future 
perspectives
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Best practice for patients with multi-organ metastatic colorectal cancer may not only 
involve optimal palliative treatment with systemic therapy but also local treatment of 
metastases, provided that this improves quality of life or overall survival while maintaining 
quality of life. Current evidence based practice is systemic therapy with doublet or triplet 
chemotherapy combined with targeted therapy. Only a few  criteria have shown clinical 
value in treatment selection. Patients with a left-sided primary tumor and wild type RAS 
or BRAF are selected for treatment with anti-EGFR agents [1,2], patients with a tumor 
harbouring a BRAF mutation for treatment with cetuximab and encorafenib [3] and lastly, 
patients with a microsatellite instable tumor are selected for immunotherapy [4]. In the 
multidisciplinary team, local treatment of metastases is frequently considered if this is 
technically feasible. However, in the setting of multi-organ metastatic CRC, no randomized 
clinical evidence is available to support this strategy.
There is a clinical need for evidence of overall survival benefit for this multi-modality 
treatment strategy, as well as data on the feasibility of performing a combination of different 
local treatment modalities to treat metastases without interrupting chemotherapy for too 
long. Due to the time needed for these treatment strategies as well as recovering from 
treatment and/or potential complications may reduce their potential benefit. 
Part One: Debulking in metastatic colorectal cancer
In Chapter 2 the rationale of tumor debulking is reviewed.  There are theoretical benefits 
of tumor debulking in patients with extensive disease, but thus far there are no clinical 
data to support this. One could postulate that organ dysfunction could possibly be 
prevented by reduction of tumor burden, thereby improving the performance status 
and tolerance of systemic therapy. In addition, after removal of poorly vascularised 
tumors and drug-resistant clonal cells, the limited tumor residue may be better perfused 
making it more responsive to cytotoxic agents. Moreover, reduction of the total tumor 
mass may alleviate the associated immunosuppressive effects and thereby enhance host 
immunocompetence, all potentially improving overall survival. A parallel was made to 
ovarian carcinoma, where tumor debulking is standard practice. Although contrary 
to mCRC, metastatic ovarian carcinoma is characterized by mainly spreading in the 
abdominal cavity and rarely hematogenous dissemination, the benefits could still hold 
true for mCRC. With all advances in minimal invasive procedures and perioperative care, 
the balance between doing harm and benefit for the patient may have evolved over 
the last decades. Retrospective data and series on local treatment procedures in mCRC 
hold promise on local control and (overall) survival for these patients. However, literature 
review revealed that no evidence based data is available for clinical decision making so far. 
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We hypothesized that tumor debulking could improve overall survival in patients with 
multi organ metastatic colorectal cancer. To study this, we initiated a phase III randomized 
clinical trial.
The ORCHESTRA trial
The ORCHESTRA trial is ‘A randomized multicenter clinical trial for patients with multi 
ORgan, Colorectal cancer metastases comparing the combination of cHEmotherapy and 
maximal tumor debulking versuS chemoTheRapy Alone’. 
A multidisciplinary collaboration was initiated between principle investigators from the 
Medical Oncology department from Amsterdam UMC (Location VUmc) and the Surgical 
Oncology department from the ErasmuMC Cancer Center. A writing committee including 
specialists from both departments as well as specialists in radiotherapy and interventional 
radiology have drawn up the research protocol. Patients representatives from the Stichting 
voor Patienten met Kanker aan het Spijsverteringskanaal (SPKS: foundation for patients 
with cancer of the gastrointestinal tract) were involved in reviewing the protocol and the 
patient information sheet. 
The protocol fits in with daily practice in colorectal cancer care, to allow the results to 
be readily implemented in daily practice. Eligibility criteria were drawn up in a way that 
patients who were fit for systemic therapy could be included in the study, provided that 
debulking of 80% of metastatic disease was deemed feasible by the local multidisciplinary 
team.  At study inclusion, baseline CT-scans of thorax and abdomen were reviewed by 
a second surgical oncologist / intervention radiologist / radiotherapist as appropriate 
from the VUmc or ErasmusMC to confirm feasibility of tumor debulking. The study was 
financially supported by a not-for-profit foundation Blokker-Verwer, the Dutch Cancer 
Foundation (KWF) and a non-restricted grant from Roche. The study was endorsed by the 
Dutch Colorectal Cancer group.
After approval from the Ethical Committee and the CCMO, the first patient was included 
in May 2013. Patient inclusion was characterized by a start-up phase with slow patient 
accrual. This reflects the time consuming process of obtaining local approval in different 
participating centers as well as initial unfamiliarity with the logistic implications of the 
trial protocol.[5] It was challenging to get consensus on feasibility of tumor debulking, 
which may potentially be hampered by a lack of clinical equipoise of members in the 
multidisciplinary team. Studies have shown potential discrepancies between perception 
of resectability between medical oncologists and hepatic surgeons.[6] Teams including 
experts in specific treatment (i.e. liver resection) seem to identify more patients who are 
potentially resectable.[7] Generally, a certain reluctance towards metastatic resections in 
clinical practice was observed in a central evaluation of the FIRE-3 trial. [8] Commitment 
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and close collaboration grew in time in the participating centers that include patients. 
In this large prospective cohort patients will be followed up until the date of death, to 
evaluate overall survival. 
Patients included in the ORCHESTRA have multi-organ metastatic disease. The main 
treatment goal is therefore palliative care where solid evidence on increasing overall 
survival with systemic therapy is available. However, quality of life is the corner stone in 
every treatment decision. These patients are a vulnerable patient category who were most 
times just recently informed about the incurable state of their disease. We did our utmost 
effort to inform them well on the potential risks and benefits of the study. Safety issues 
were continuously monitored for by adverse events reporting. An independent Data 
Safety Monitoring board evaluated safety after the first 25, 50 and 100 patients included. 
After inclusion of the first 100 patients, a preplanned safety and feasibility evaluation was 
performed, to confirm feasibility and evaluate safety risks in the trial. 
In Chapter 3 our objective in was to demonstrate the feasibility of debulking (by local 
treatment) of metastases in addition to systemic therapy in patients with multi-organ 
mCRC. We reported adverse events of performing (a combination of different) local 
treatment modalities like resection, stereotactic radiotherapy and thermal ablative 
therapy to treat metastases. 
We showed that tumor debulking is feasible and does not prohibit administration of 
palliative chemotherapy in the majority of patients with multi-organ mCRC. Completing 
tumor debulking had substantial impact for the patients involved. Inevitably, serious 
adverse events occurred.  However, the morbidity and  90-day mortality is comparable to 
previous studies on surgical resection of CRC liver metastases.[9-13] Patients randomized 
in arm B who underwent debulking after 7 cycles of systemic therapy, due to stable 
disease at first evaluation, did not have more SAEs related to the procedures despite 
having received more cycles of chemotherapy.[14] 
To our knowledge, only one prospective study on patients with resection for extrahepatic 
disease has been published by Wei et al. This phase II study of metastasectomy for both 
intrahepatic and extrahepatic disease enrolled 26 patients with generally less extensive 
disease.[13] To prevent tumor progression and poor oncological outcome we aimed for 
a short chemotherapy free interval.[12] Systemic therapy was resumed within a median 
of 12.5 weeks after finishing preoperative chemotherapy. There was a median of 5 weeks 
interval between last local treatment and start of postoperative chemotherapy, which 
could be considered a ‘morbidity associated chemotherapy interval’, this compared 
favorably to reports on patients undergoing two stage hepatectomy for resectable CRC 
liver metastases, [10] or major hepatectomy (≥3 segments) for mCRC. [12]
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Patients with multiorgan mCRC
 ARM B ARM A
Response or Stable Disease
Continue systemic therapy








3 cycles CAPOX or 4 cycles FOLFOX
± bevacizumab




Figure 1. Simplified flow-chart of ORCHESTRA study protocol.
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Since systemic therapy is the evidence based treatment for these patients, we endeavored 
not to compromise on the amount of systemic therapy given in the intervention arm. In 
our cohort there was no significant difference in the amount of cycles of systemic therapy 
given between the study arms, and a comparable proportion of patients completed at 
least 8 cycles of CAPOX(±B) (or the equivalent in FOLFOX) in both treatment arms. 
EORTC quality of life (C30) and Multidimensional Fatigue Inventory questionnaires were 
obtained with 3 months interval in the first year on study. The impact on patient reported 
quality of life changes will have to be analyzed and assessed in the light of potential 
overall survival benefit and objective procedure related risks and burden of hospital stay. 
Implications for practice
This first prospective randomized trial on tumor debulking in addition to chemotherapy 
shows that local treatment of metastases is feasible in patients with multi organ mCRC and 
does not prohibit administration of palliative systemic therapy, despite the occurrence 
of serious adverse events related to local treatment. The trial continues accrual and OS 
data and quality of life assessment are collected to determine whether the primary aim 
of >6 months OS benefit with preserved quality of life will be met. This will support 
evidence based decision making in multidisciplinary colorectal cancer care and can be 
readily implemented in daily practice, with data on potential benefit and risks available 
to discuss with the patient. Other efforts are made on the subject, with the LUNA trial 
(NCT02738606) - a phase II single-institution randomised trial randomising patients with 
resectable liver metastases and unresectable (but low volume) lung metastases between 
liver resection plus chemotherapy and chemotherapy without liver resection open for 
accrual at MD Anderson.
Although local treatment of metastases might be feasible with current local treatment 
modalities in an increasing number of patients with mCRC, only overall survival benefit 
while maintaining the quality of life can confirm that this is the preferred palliative 
treatment approach. The ongoing trials will provide clinical evidence for this approach 
and will improve multidisciplinary decision-making in patients with mCRC.
Part Two: Predicting response to systemic therapy
All patients enrolled in the ORCHESTRA study start with palliative systemic therapy, to 
be randomized to continuation of systemic therapy or debulking in addition to systemic 
therapy after completion of at least 3 cycles of CAPOX (B) or 4 cycles of FOLFOX(B). (see 
figure 1) To maximize the value of all clinical data collected a biopsy of a metastasis at 
baseline as well as baseline  and follow-up blood samples were collected to get in-depth 
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information on tumor and patient characteristics. We aimed to identify patients who will 
respond to systemic therapy or are intrinsically resistant and progress despite systemic 
treatment. 
MicroRNA
In Chapter 4, we aimed to validate the predictive value of a previously identified miRNA 
profile combined with clinicopathological factors in predicting early response to first line 
palliative systemic therapy in advanced mCRC in the ORCHESTRA study cohort [15]. The 
same miRNA profile was quantified in serum specimens to test its predictive value as a 
liquid biomarker. 
The predictive value of the tissue derived miRNA profile combined with the 
clinicopathological factors could not be validated in patients with mCRC starting with 
first line systemic therapy. Compared to the cohort previously used for identification of 
the putative predictive profile, the clinical parameters of the ORCHESTRA cohort differed 
significantly with the most important difference being that this cohort consisted of only 
patients with stage IV disease (whereas the original cohort had 32% stage I-III disease). 
Studies have shown that expression levels of specific miRNAs differ between clinical 
tumor stages [16, 7], but not specifically for the miRNAs in our profile. [18-21]. Moreover, in 
the original prediction model the  chemotherapeutic regimen was an important covariate 
whereas all patient in ORCHESTRA were treated with the same regimen. 
Methodologically, there were some differences in in RNA extraction and quantification, 
due to updated kits available from Qiagen, resulting in significantly higher expression of 
the miRNAs in the updated assay.  Lastly, the biopsy specimens in this cohort consisted 
of fresh frozen tissue, mainly from metastatic lesions, whereas in the original FFPE cohort 
biopsies consisted of formalin fixed paraffin embedded (FFPE) tissue samples, mainly from 
the primary tumor. However, studies have shown good correlations between miRNAs 
quantified in paired FF and FFPE samples independent of the employed methodology [22-
25]. We previously demonstrated that miRNA profiles of primary tumor and metastases are 
similar, making the biopsy site an unlikely explanation for differences in miRNA expression 
levels [26]. 
With respect to the serum expression levels, three out of six miRNAs also originate from 
blood cells (miR-17-5p, miR-92a-3p and miR-20a-5p) and therefore have high baseline 
serum expression levels [27, 28]. Consequently, miRNAs released from tumors may be 
insufficient to significantly alter these high baseline levels. On the contrary, miR-30a-5p, 
miR-92b-3p and miR-98-5p were proven to have low baseline serum expression levels, but 
are also expressed at low levels in CRC tissue. Nevertheless, previous studies have identified 
a predictive and/or prognostic value in CRC of serum expression levels of four (miR-17-5p, 
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miR-20a-5p, miR-30a-5p, miR-92a-3p) of the six miRNAs selected for this study [29-31]. 
Probably other factors, for example the composition of the tumor microenvironment, the 
percentage of immune cell infiltration or circulating inflammatory indicators, which are 
also important factors for therapy response, may alter circulating miRNA levels as well. 
Although in our dataset the addition of miR-92a-3p and miR-98-5p significantly improved 
the AUC of the ROC curve for predicting response to chemotherapy, the predictive value 
remains moderate and as such not useful in clinical practice. To reduce background noise 
of endogenous miRNAs in blood cells, miRNAs could be quantified in exosomes. It is 
hypothesized that exosomes released from tumor cells are enriched with a tumor specific 
miRNA signature [32].  
Despite the known role of miRNAs in cancer biology and their favorable characteristics to 
serve as biomarkers, the predictive miRNA signature which was previously identified did 
not show significant strength to predict treatment benefit in the present sizeable cohort 
of patients with mCRC undergoing first line combination chemotherapy. This could be 
partly due to differences in patient population and the materials and methods used. It 
emphasizes the importance of thorough research on miRNAs as a predictive marker prior 
to using it in clinical decision making. Potential improvements, by selecting miRNAs in 
circulating vesicles may provide additional value in this matter and requires additional 
evaluation. 
Circulating Endothelial Cells
From patients enrolled in the ORCHESTRA study, blood samples were collected in CellSave 
preservative tubes to evaluate the prevalence of tumor derived circulating endothelial 
cells (CD276+CEC) measured by flowcytometry in patients with mCRC and explore the 
predictive value for response to systemic therapy. Previous studies evaluating CEC using 
(CD34+CD45negDNA+CD146+) for CEC identification focused mainly on predicting survival 
in patients treated with first line systemic therapy for mCRC by using the CellSearch 
system (by Veridex®) [33-35]. The flow cytometry enumeration we used, as described 
before by Kraan et al. has the same markers for CEC identification, albeit with different 
fluorescent antibodies. CEC counts demonstrated to correlate well with CellSearch system 
counts, with a slightly higher recovery [36]. Other studies used flow cytometry for CEC 
enumeration with different cluster of differentiation markers.[37-39] 
In Chapter 5 we report the detection of CECs by FACS analysis in all patients with a range 
from 2-1627 per 4 ml blood and CD276+CECs were measured in all but one patient, ranging 
from 0-1608/4 ml. The median CEC count of 48.5/4 ml (12/ml) is higher than reported by 
others using the same markers. Simkens et al reported a median of 6.8 CEC/ml in a large 
population of 435 patients[33]. Studies from CEC counts prior to liver resections reported 
5/ml (CellSearch, 140 patients) or 10 vs 20/ml  for patients with respectively good (N = 102) 
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or poor (N=52) outcome, (CD34+CD45-CD146+ measured by FACS). [35, 39]. In our study, a 
significant higher CEC count after 3 cycles of chemotherapy (p=0.00), with a nearly 2-fold 
increase (48 to 90/ 4 ml) was detected. This is in line with the findings of Simkens who 
reported a 1.5 fold increase (median CEC from 6.8 to 10.5/ml after 6-12 weeks), which was 
not prognostic for PFS or OS [33].
Our aim was to identify patients who progress within 6 months of start with therapy by 
(CD276+)CEC counts. The AUC of the ROC for CEC counts duration of response < 6 months 
was 0.53 and 0.52 for CD276+CEC counts, indicating that measuring (CD276+)CECs is a 
poor test to predict response to therapy. No clinical relevant cut-off value could be 
established. Baseline (CD276+)CEC counts were not significantly different for any baseline 
clinicopathological variable. 
Since circulating endothelial cells act as a surrogate marker of endothelial damage, 
counts can increase in a variety of conditions including ischemia, infections, vascular or 
autoimmune disease. All baseline samples were taken prior to start of systemic therapy. 
Previous adjuvant systemic therapy did not include bevacizumab and was at least 6 
months prior to inclusion and is therefore less likely to influence measurements. Patients 
were not randomized to receive bevacizumab or not. No significant differences in baseline 
CEC and CD276+CEC counts between patients that did or did not receive bevacizumab 
were detected. 
Kinetics of CECs have been studied with varying results. Murine models showed that 
VEGF pathway inhibitors can have differential effects on CECs in that inhibition of 
tumor angiogenesis is associated with an initial increase in mature CECs, followed by 
a subsequent reduction[40]. We found a significant increase in CEC and CD276+CEC 
counts during treatment with chemotherapy combined with bevacizumab. The subset of 
CD276+CEC decreased from 40% to 35% (p=0.05). Prior studies showed conflicting results 
on the direction of change. [33, 38, 41]. 
In conclusion, CD276+CEC counts can be measured in patients with mCRC, but no 
correlation with clinical parameters was demonstrated. Cell counts increased during 
systemic therapy. In patients treated with bevacizumab, CEC and CD276+CEC counts 
in follow up samples were lower compared to patients not treated with bevacizumab. 
Despite numerical changes during therapy, (CD276+)CEC counts alone do not adequately 
predict poor response to first line palliative systemic therapy in patients with mCRC.
Radioemitter labelled antibody imaging
In our journey to evaluate minimally invasive tests to predict response to systemic therapy, 
we explored the potential of 89Zr-cetuximab PET imaging  in predicting response to the 
7
Discussion   |   129 
anti-EGFR  agent cetuximab. Ultimately, we aim to develop a PET-imaging guided tool to 
select patients who could benefit from cetuximab treatment.
In Chapter 6 we report the results of a pilot study evaluating  89Zr-cetuximab PET imaging 
in patients with wt K-RAS mCRC. Tumor uptake of 89Zr-cetuximab in 6 out of 10 patients of 
whom 4 had clinical benefit of cetuximab treatment was observed. Based on the design 
of this clinical trial in which uptake in ≥1 of 10 or ≤ 7 of 10 patients (power >90%, type I 
error <5%) was expected, tumor uptake of 89Zr-cetuximab may be used to predict clinical 
benefit of cetuximab in patients with wt K-RAS mCRC, which should be further validated 
in a larger cohort of patients. 
First, we investigated whether our model optimally reflected the biodistribution of 
unlabeled cetuximab. We were challenged by immediate binding of the labeled mAb 
to easy accessible non tumor sites, e.g. liver, as demonstrated in studies evaluating 111In-
C225 in patients with squamous cell lung carcinoma and 89Zr-trastuzumab in patients 
with HER2 positive metastatic breast cancer. Administration of unlabeled antibody is used 
to saturate non tumor sites. [42, 43] As a proof of principle, we administered a scouting 
dose of 0,1 mg 89Zr-cetuximab before the unlabeled therapeutic dose of cetuximab in 
three patients. In blood samples taken 2 and 3 hours after administration of the scouting 
dose,  only <10 %ID 89Zr-cetuximab could be detected. However, by administration of 
the therapeutic dose of 500 mg/m2 cetuximab before the labeled fraction, sufficient 
89Zr-cetuximab was found in the blood pool for tumor targeting. In addition, the half-
life  of 89Zr-cetuximab if co-administered with the therapeutic dose, is comparable to 
unlabeled cetuximab, indicating that in our model 89Zr-cetuximab reflects biodistribution 
of unlabeled cetuximab. 
Tumor uptake was initially evaluated by visual assessment, which implies contrast with 
background activity. The optimal scanning time point is the 6th day post injection, which is 
in line with literature and expected based on the t½ of 
89Zr.[44] The subsequently calculated 
SUVpeak at day 6 p.i. can discriminate between lesions with and without visible uptake and 
suggests that a cut-off SUVpeak could be helpful in the determination of specific uptake 
versus background activity. Because a significant amount of the ID of 89Zr-cetuximab 
accumulated in the liver, hepatic metastases were unsuitable to evaluate tumor uptake 
as spill-over from uptake in adjacent normal liver tissue hampered adequate uptake 
evaluation of tumor sites. With the liver being a common metastatic site of mCRC this can 
limit the use of 89Zr-cetuximab as a treatment selection tool.
The data in this study are too limited to draw conclusions on the correlation between 
blood concentration, liver uptake, tumor targeting and response. Of 6 patients showing 
89Zr-cetuximab uptake, 4 had clinical benefit. Since patient accrual started prior to the 
knowledge of the negative predictive value of N-RAS and BRAF mutations, the absence 
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of response in the remaining two patients may be due to N-RAS or other mutations. 
Unfortunately, no adequate tumor material was available for further assessment of 
the mutational status in these patients. One patient had clinical benefit, although 89Zr-
cetuximab uptake could not be visualized. Possibly, the amount of cetuximab that reached 
the tumor was insufficient for visual assessment, but did induce anti-tumor activity, for 
example by antibody-dependent cell-mediated cytotoxicity.[45]
In conclusion, PET-imaging with 89Zr-cetuximab is feasible. Despite relatively high liver 
uptake, variable tumor uptake can be demonstrated in metastases of patients with wt 
K-RAS colorectal carcinoma by visual assessment of 89Zr-cetuximab PET scans. The optimal 
scanning time point appears to be at day 6 post radiotracer injection. With 6 of 10 patients 
showing uptake, statistical conditions were met for 89Zr-cetuximab imaging to qualify as a 
potential treatment selection tool. 
Based on the pilot results, a prospective clinical trial investigated whether tumor uptake 
on 89Zr-cetuximab PET scan could guide dose escalation to improve the clinical response 
(NCT02117466). Visual uptake on 89Zr-cetuximab PET/CT was observed in 66% of 35 
patients, but no relationship between PET-positivity (p=0.16)and treatment benefit, 
progression-free survival (p = 0.15) or overall survival (p = 0.29) was demonstrated. In 
addition, tumor SUVpeak did not correlate to changes in tumor size on CT, treatment benefit 
nor progression-free survival. Eighty percent of patients without visual tumor uptake had 
treatment benefit, making 89Zr-cetuximab PET unsuitable as predictive biomarker.[46] 
Although imaging of labeled antibodies is a promising tool in the field  of response 
prediction biomarkers, however 89Zr-cetuximab PET/CT does not meet the necessary 
criteria to fulfill this need. 
Summarizing conclusions and future directives.
The ORCHESTRA trial is a multicenter clinical trial that will generate important information 
for clinical decision making in multidisciplinary colorectal cancer care. The interim report 
on safety and feasibility supported study continuation. With joint effort in all participating 
hospitals, the trial will continue accrual to meet its primary end-point. Despite the 
promising characteristics of CD276+CECs and  the previously validated miRNA profile as 
a biomarker, both could not adequately predict response to first line systemic therapy.  
With the acknowledgement of the Consensus Molecular Subtypes [47], it is fair to assume 
that the four different subtypes represent different diseases and predicting response 
should be tailored to each group. Most likely, integrated analysis like the basis of the 
CMS will be needed for accurate prognosis of response to therapy and survival. Although 
CMS was not designed for prediction or prognosis purposes, it performed fairly well in 
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the CALGB/SWOG 80405 cohort. [48] Prior analysis showed that chemotherapy effects 
CMS subtypes on primary tumor material [49]. Our dataset includes tissue of metastases 
biopsied just prior to start of therapy and on treatment samples and will provide valuable 
information on actual tumor characteristics in the metastatic setting just prior to start of 
systemic therapy within the limits of tumor heterogeneity and sampling error. 
Unravelling tumor characteristics in this tumor stage will help understand tumor behavior 
in the metastatic setting and select patients who may benefit from more or less aggressive 
approach in both systemic as well as local treatment options. Finding minimally invasive 
ways to collect this information should be an ongoing effort focused on liquid biopsies. 
The ORCHESTRA trial meets the large need for adequate tissue and blood sample 
collection in prospective trials[50] and will serve as a rich database for future research. 
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SAMENVATTING
Gemetastaseerd colorectaal carcinoom (mCRC) is een belangrijke oorzaak van kanker 
gerelateerde sterfte in Nederland. Twintig procent van de patiënten presenteert zich met 
afstandsmetastasen ten tijde van diagnose. Uiteindelijk wordt bij 50% van de patiënten 
afstandsmetastasen vastgesteld. Veelvoorkomende lokalisaties van metastasen zijn 
lever, longen, lymfklieren, peritoneum en zeldzamer de bijnier, botten en hersenen. Met 
de huidige systemische therapie, bestaande uit doublet of triplet chemotherapie  en 
doelgerichte therapieën is de mediane overleving van patiënten met mCRC toegenomen 
van 9 tot ongeveer meer dan 30 maanden. Voor patiënten met uitzaaiingen in meerdere 
organen is de prognose echter somberder. 
Bij mCRC patiënten met oligometastasen worden metastasen met curatieve intentie 
gereseceerd. Bij complete resectie van lever- of longmetastasen verbetert de 5-jaars 
overleving tot 35-60% en kan zelfs langdurige overleving worden bereikt in geselecteerde 
patiënten. Slechts in 5 tot 20% van de patiënten is chirurgische resectie van lever en/of long 
metastasen echter haalbaar. Betrokkenheid van meerdere organen, metastasen in para-
aortale lymfklieren of  bijnier en de aanwezigheid van meer dan 5 levermetastasen bleken 
slechte prognostische factoren voor overleving in deze geselecteerde patiëntengroepen. 
Bij lokale behandeling van multi-orgaan uitzaaiingen zou je kun spreken van 
tumordebulking, omdat je er vanuit kunt gaan dat er residuale ziekte overblijft. 
Deel 1: Tumor debulking bij patiënten met uitgebreid 
uitgezaaide darmkanker.
In Hoofdstuk 2 wordt de rationale van tumordebulking bij uitgezaaide darmkanker 
besproken aan de hand van de beschikbare literatuur. Tumor debulking is onderdeel van 
de standaard behandeling voor patiënten met een gemetastaseerd ovariumcarcinoom, 
aangezien dit overlevingswinst geeft. De studies naar tumor debulking bij mCRC zijn 
echter vaak klein, niet gerandomiseerd of retrospectief, maar ondersteunen de gedachte 
dat reductie van de tumorvolume wellicht overlevingswinst oplevert, ook wanneer de 
debulking incompleet is. Het is onduidelijk wat de toegevoegde waarde is van lokale 
anti tumor behandelingen aan de verbeterde chemotherapie regimes aangezien 
gerandomiseerde studies ontbreken. Prospectieve studies waarin  palliatieve systemische 
behandeling en tumor debulking gecombineerd worden zijn nooit uitgevoerd in 
patiënten met multi-orgaan mCRC. 
Met de ontwikkeling van nieuwe behandelmodaliteiten is lokale behandeling van 
metastasen steeds vaker mogelijk. Zowel radiofrequente ablatie (RFA) van metastasen in 
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long en lever en stereotactisch bestralen (SABR) van lever, long, bijnier of botmetastasen 
worden succesvol uitgevoerd. Door deze modaliteiten te combineren, is tumor debulking 
bij meer patiënten haalbaar. Het is echter onduidelijk of dit ook overlevingswinst oplevert 
voor patiënten die palliatief worden behandeld met systemische therapie.  
Om dit te onderzoeken is de ORCHESTRA trial opgezet. Een onderzoek voor patiënten met 
uitgezaaide darmkanker waarbij behandeling met een combinatie van chemotherapie en 






Figuur 1: ORCHESTRA studie. 
Patiënten met multi-orgaan gemetastaseerd colorectaal carcinoom (mCRC) worden gerandomiseerd 
tussen systemische therapie gecombineerd met maximale tumor debulking en behandeling met 
alleen systemische therapie.
ORCHESTRA: studie opzet
De ORCHESTRA trial is de eerste prospectieve, multicenter klinische trial waarin de 
toegevoegde waarde van tumor debulking aan palliatieve systemische therapie zal worden 
vastgesteld. Patiënten met multi-orgaan mCRC worden gerandomiseerd tussen systemische 
therapie gecombineerd met maximale tumor debulking, bestaande uit chirurgie, RFA en/of 
SABR, en behandeling met alleen systemische therapie (Figuur 1). Het primaire eindpunt 
van de studie is overall survival. De studie is gepowered om tenminste zes maanden 
overlevingsvoordeel aan te tonen. In totaal zullen 478 patiënten worden geïncludeerd. Een 
belangrijk secundair eindpunt is de kwaliteit van leven. Dit zal regelmatig met behulp van 
vragenlijsten geëvalueerd worden. Overige secundaire doelen zijn het vaststellen van de 
progressie vrije overleving en biomarker onderzoek naar respons predictie. Voor dit laatste 
zal bij alle patiënten een tumorbiopt worden afgenomen voor start van de chemotherapie 
en worden er sequentieel bloedmonsters afgenomen.
Patiënten met naar meerdere organen gemetastaseerd CRC met een indicatie voor eerste 
lijn palliatieve behandeling kunnen deelnemen aan de studie. De belangrijkste in- en 
exclusie criteria zijn samengevat in tabel 1. De opzet van de trial is op vereenvoudigde 
wijze weergegeven in een stroomdiagram (Figuur 2).
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Tabel 1
Belangrijke inclusie criteria
•  Patiënten met  een indicatie voor eerste lijn palliatieve systemische therapie voor mCRC
•  Gemetastaseerd colorectaalcarcinoom ≥2 organen  en tenminste:
>1 extrahepatische metastasen of  
>5 levermetastasen in meer dan één kwab of 
≥1 levermetastasen en positieve para-aortale of coeliacale klieren of bijniermetastasen of pleuritis 
carcinomatosa of peritonitis carcinomatosa. 
•  Beoordeling expertteam: ten minste 80% tumor debulking haalbaar 
Multi Disciplinaire Beoordeling 
Een multidisciplinair expertteam bestaande uit een radioloog, oncoloog, chirurg en 













Figuur 2: Stroomdiagram Studie opzet
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Behandeling
Patiënten in beide onderzoeksgroepen starten met standaard systemische behandeling 
(3 kuren capecitabine en oxaliplatin ± bevacizumab of 4 kuren 5FU/LV, oxaliplatin ± 
bevacizumab) waarna een evaluatie CT scan volgt. Indien er bij de eerste evaluatiescan 
reeds progressie van ziekte (conform RECIST 1.1) is, wordt de patiënt niet gerandomiseerd. 
Bij respons of stabiele ziekte wordt de patiënt gerandomiseerd tussen de standaard arm 
waarin met systemische therapie gecontinueerd wordt (arm A), of de interventie arm (arm 
B). Voor patiënten in arm B zal een definitief behandelplan wordt opgesteld. De lokale 
behandeling wordt bij voorkeur binnen 3 maanden na de laatste kuur uitgevoerd. Nadien 
wordt de systemische therapie hervat. De systemische therapie wordt gecontinueerd tot 
progressie van de ziekte of onverdraagbare toxiciteit.
In Hoofdstuk 3 worden de resultaten van de tussentijdse evaluatie van veiligheid en 
haalbaarheid beschreven die conform protocol werd uitgevoerd na inclusie van de eerste 
100 patiënten. Dit liet zien dat het haalbaar is om binnen een acceptabele periode van 
3 maanden een combinatie van lokale behandelingen zoals resectie, SABR en/of RFA 
uit te voeren bij patiënten die voorbehandeld zijn met chemotherapie, en dat in 89% 
de chemotherapie postoperatief weer hervat kon worden. Onvermijdelijk traden er ook 
ernstige ongewenste voorvallen op in de patiëntengroep die (een combinatie) van lokale 
behandelingen van metastasen onderging in het kader van studie. De morbiditeit en 
90-dagen mortaliteit is echter vergelijkbaar met studies waarin resectie van colorectale 
levermetastasen wordt onderzocht. We streefden naar een zo kort mogelijke onderbreking 
van de chemotherapie voor het uitvoeren van de lokale behandelingen. Bij de patiënten 
in de interventie arm kon de chemotherapie kon binnen mediaan 12.5 weken na het 
afronden van de preoperatieve chemotherapie hervat worden. Tussen de laatste lokale 
behandeling en het starten van de postoperatieve chemotherapie zat mediaan 5 weken. 
Er was geen significant verschil tussen het aantal cycli chemotherapie dat patiënten in de 
interventie arm versus de patiënten in de standaard arm kregen.
Samenvattend zijn lokale behandeling van metastasen met de huidige 
behandelmodaliteiten zoals chirurgie, RFA, en stereotactisch bestralen steeds vaker 
mogelijk. Dit lijkt ook haalbaar bij patienten met uitgebreid uitgezaaide ziekte, waarbij 
de morbiditeit vergelijkbaar is met een minder uitgebreid uitgezaaide patiëntengroep. 
En hoeven er geen concessies te worden gedaan aan de hoeveelheid chemotherapie die 
patiënten krijgen. 
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Deel twee: Het voorspellen van respons op systemische 
therapie
Een belangrijk doel van deze trial is onderzoek naar biomarkers die respons op 
chemotherapie of overleving kunnen voorspellen. Hiervoor is bij alle patiënten een 
tumorbiopt afgenomen voor start van de chemotherapie en zijn er sequentieel 
bloedmonsters afgenomen.
MicroRNA
MicroRNAs (miRNAs) zijn kleine niet-coderende stukjes RNA die invloed hebben op veel 
belangrijke biologische processen door regulatie van eiwitexpressie. Daarnaast hebben 
miRNAs gunstige kenmerken om te fungeren als biomarker, aangezien ze makkelijk te 
detecteren zijn en niet snel worden afgebroken. Eerder is aangetoond dat er verschillen 
zijn in miRNA profielen tussen normaal en tumorweefsel en tussen verschillende tumoren. 
Daarnaast is vastgesteld dat miRNA van tumorcellen in de circulatie worden uitgescheiden 
en derhalve in bloed kunnen worden gedetecteerd. 
In Hoofdstuk 4, hebben we de voorspellende waarde van een eerder geïdentificeerd 
miRNA profiel getracht te valideren. In een eerdere studie stelden we op basis van 
next generation sequencing data van samples van primaire tumoren een model op dat 
respons op palliatieve chemotherapie kon voorspellen. Dit bestond uit expressie van 
zes miRNAs (miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and miR-
98-5p) gecombineerd met 4 klinische parameters (eerdere behandeling met adjuvante 
chemotherapie, leeftijd, tumor differentiatie en type systemische behandeling dwz. 
oxaliplatin of irinotecan gebaseerd).  Het 6-miRNA profiel is zowel in biopten van metastasen 
als in serum van de geïncludeerde patiënten gemeten. De voorspellende waarde van 
dit profiel, gecombineerd met de 4 klinische parameters kon niet worden gevalideerd 
in het ORCHESTRA cohort. Het cohort waar het profiel op gebaseerd is verschillende 
op een aantal punten van het ORCHESTRA cohort, met name dat in de ORCHESTRA trial 
alleen patiënten met stadium IV ziekte zitten en alle patiënten met CAPOX(B) werden 
behandeld, in tegenstelling tot het originele cohort, waarin ook patiënten met stadium 
1-3 ziekte zaten en er verschillende behandelregimes gebruikt werden. In methodologisch 
opzicht was verschil in RNA extractie en kwantificatie als gevolg van updates in de 
commercieel verkregen kits, waardoor er significant hogere expressieniveaus werden 
gemeten. Tenslotte waren de weefselsamples in het ORCHESTRA cohort allemaal vers 
ingevroren weefsel van biopten uit een metastase, in tegenstelling tot de FFPE biopten 
van primaire tumoren in het originele cohort. In het ORCHESTRA cohort bleek dat het 
toevoegen van miR-92a-3p en miR-98-5p expressieniveaus aan de klinische parameters 
in het model voor het voorspellen van respons op chemotherapie significant verbeterde. 
De totale voorspellende waarde bleef echter maar matig en derhalve ongeschikt in de 
144   |   Appendices
dagelijkse kliniek. Ondanks de bekende rol van miRNAs in kanker biologie en de gunstige 
eigenschappen als biomarker, hebben wij de voorspellende waarde van het 6-miRNA 
profiel niet kunnen valideren.
Circulerende Endotheel Cellen
Circulerende endotheel cellen (CECs) zijn cellen afkomstig van beschadigde normale 
en tumor vasculatuur. In vergelijking met gezonde vrijwilligers zijn CEC waarden vaak 
verhoogd in patienten met uitgezaaide maligniteiten.  Uitgangswaarden van CECs, maar 
ook veranderingen in CEC aantallen gedurende therapie zijn eerder in verband gebracht 
met prognose. Er is weinig bekend over de waarde van CECs in het voorspellen van 
respons op chemotherapie. Eerder onderzoek beschreef een methode om specifieke 
tumor-afkomstige CECs te meten op basis van CD276 expressie.  Dit zou de specificiteit en 
daarmee de voorspellende waarde kunnen verhogen. Tumorcellen brengen CD276 laag 
tot expressie, maar tumor geassocieerde endotheelcellen brengen dit hoog tot expressie. 
Kraan et al. ontwikkelden een detectiemethode voor tumor afkomstige CD276+CECs op 
basis van flowcytometrie (FACS) op basis van (CD34+CD45negDNA+CD146+). 
In hoofdstuk 5 worden de resultaten van metingen van (CD276+)CECs in bloed van 
patiënten in de ORCHESTRA trial gerapporteerd. Het primaire doel van de studie was 
om de prevalentie van (CD276+)CECs in patiënten met mCRC vast te stellen en de 
veranderingen hierin gedurende systemische therapie te beschrijven. Met FACS analyse 
konden CECs en (CD276+)CECs worden gemeten. Na 3 kuren chemotherapie verdubbelde 
het aantal CECs, maar het aantal tumorspecifieke CD276+CECs daalde. De subset het aantal 
CD276+CECs van het totaal aantal CECs daalde significant. We vonden geen relatie tussen 
baseline (CD276+)CEC waarden met andere klinische of pathologologische parameters. 
Zowel de uitgangs (CD276+)CECs waarden, als de verandering gedurende thearpie waren 
niet voorspellend voor progressieve ziekte binnen 6 maanden na start van eerstelijns 
palliatieve systemische therapie. 
PET-scan met Radioactief gelabelde antistoffen.
Hoofdstuk 6 beschrijft een heel andere manier om respons op systemische therapie 
te voorspellen. In dit hoofdstuk worden de resultaten van een studie met 89Zr gelabeld 
cetuximab PET-scans bij patiënten met K-RAS wild type mCRC beschreven. In deze pilot 
studie werd de dosering en de timing van de PETscans geoptimaliseerd Bij 6 van de 10 
patiënten werd visuele uptake van 89Zr-cetuximab waargenomen. Vier van deze patiënten 
bleken uiteindelijk baat te hebben van de therapie. Een aandachtspunt bij deze methode 
is de grote hoeveelheid gelabelde antistof die bind in de lever, waardoor levermetastasen 
– frequent voorkomend bij mCRC – niet beoordeeld kunnen worden. Het onderzoek werd 
later vervolgd in een grotere groep patiënten om de voorspellende waarde voor respons 
op behandeling vast te stellen.
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Conclusie
De ORCHESTRA trial is de eerste prospectieve gerandomiseerde klinische trial waarin 
wordt onderzocht of toevoeging van maximale tumordebulking aan systemische 
therapie, de overleving van patiënten met multi-orgaan mCRC significant verbetert. 
Met de resultaten van de ORCHESTRA studie zal de waarde van lokale behandeling van 
metastasen in palliatieve setting vastgesteld worden. De klinische relevantie hiervan is 
aan de orde van de dag bij het formuleren van een multidisciplinair behandeladvies voor 
patiënten met mCRC. 
De uitkomsten van de veiligheids- en haalbaarheidsevaluatie ondersteunde de 
voortgang van de studie. In samenwerking met alle deelnemende centra zal de studie 
continueren tot het primaire eindpunt kan worden gehaald. Ondanks de veelbelovende 
eigenschappen van CD276+CECs en het eerder geïdentificeerde 6-miRNA profiel, konden 
we hiermee respons op eerstelijns palliatieve systemische therapie nog onvoldoende 
voorspellen.  De database met klinische gegevens en patiënten materiaal bevat een schat 
aan gegevens, die zullen worden benut naar onderzoek voor het optimaliseren van de 
zorg voor patiënten met mCRC.
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DANKWOORD
‘It takes a village to raise a child’. Bij het voltooien van dit promotieonderzoek zijn 
minstens zoveel mensen betrokken. Dit proefschrift is tot stand gekomen door een 
indrukwekkende samenwerking van patiënten, dokters, verpleegkundigen, studenten, 
onderzoekers, onderzoeksmedewerkers en nog meer bijzondere mensen die onderzoek 
naar darmkanker ondersteunen met aandacht of financiële middelen. Het is een eer om 
als promovendus mij in dit gezelschap te begeven. Samen proberen we een bijdrage te 
leveren aan het verbeteren van de zorg voor patiënten met darmkanker.
Ik wil alle patiënten en hun dierbaren bedanken voor hun deelname aan de onderzoeken 
waarvan de resultaten voor een deel in dit proefschrift zijn gepubliceerd. Uw vertrouwen 
in de behandelaren en het onderzoeksteam zijn van onschatbare waarde om onderzoek 
goed uit te kunnen voeren.
Professor Verheul, beste Henk, het vertrouwen dat je me gaf toen je me na een lange 
werkdag uit de artsenkamer van de afdeling oncologie plukte om me te polsen voor 
dit promotieonderzoek, was slechts het begin. Met alle nieuwe uitdagingen die in dit 
traject op mijn pad kwamen (inclusief de NY marathon!) kreeg ik steeds opnieuw je volle 
vertrouwen. Ik heb zoveel kunnen leren, wetende dat ik altijd bij je terecht kon als ik er 
niet uit kwam. De werkbesprekingen aan de randen van de dag waren altijd een gezellige 
start of afsluiting van het werk. Het heeft me gevormd tot de arts en onderzoeker die ik nu 
ben. Het is fantastisch om nu samen te kunnen werken in het Radboud UMC. Ik voel me 
bevoorrecht met jou als mijn mentor. We blijven steeds van elkaar leren. Dank je daarvoor.
Professor Verhoef, beste Kees, the big brother who’s watching me. Vanuit Rotterdam hield 
je een oogje in het zeil. Dank voor het denken in mogelijkheden, het enthousiasmeren 
van het team en de mensen in het veld en op z’n tijd een joviale omhelzing.
Dr. Buffart, beste Tineke, jij schudde het ORCHESTRA protocol in een paar maanden uit je 
mouw. Daarna begon jij aan de opleiding interne geneeskunde en mocht ik het stokje als 
onderzoeker van je overnemen. Je begon als mijn co-promotor, daarna werkten we samen 
als collega’s in patiëntenzorg, maar bovenal werd je daarbij mijn vriendin. Het is geweldig 
dat we zoveel in ons leven kunnen delen. Dank je voor deze waardevolle vriendschap. 
Dank aan de leden van de manuscriptcommissie, die bereid waren hun tijd en aandacht 
te besteden aan het bestuderen van mijn proefschrift. Professor Vermeulen, Professor 
Koopman, Professor Hoekstra en Professor de Wilt, mijn welgemeende dank daarvoor. 
Dr. Haasbeek, beste Niels, vele scans passeerden jouw computerscherm in de tweede 
beoordeling van de haalbaarheid van tumordebulking bij patiënten in de ORCHESTRA 
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trial. Dank dat je daar altijd tijd voor wil maken en tijdens die momenten met mij, maar 
ook de studenten die ons assisteren, je kennis deelt over stereotactische radiotherapie. 
Dr. Azad, dear Nilo, I had only just started my PhD when we first met. The collaboration 
between Professor Verheul and yourself gave me the opportunity to work with you on 
two Phase I/II trials. It has been an honour to work with you and your research team at 
Johns Hopkins and to learn from all your experience. I sincerely hope we can continue 
our collaboration in future projects. Thank you very much for taking the time to study my 
thesis and take part in the defense. 
Professor Primrose, dear John, life’s too short not to eat cod every day. The cod diet at 
Lofoten has definitely been a highlight in my ORCHESTRA career. Thank you for your never 
ending enthusiasm for this trial and perseverance in UK participation. I am very proud 
Lotte and you managed to open UK sites despite an intercurrent BREXIT and Covid19 
pandemic. This is just the beginning of our collaboration, I am looking forward to it. Thank 
you for being part of my thesis committee. It is very disappointing that we had to settle 
for an online meeting this time, but I am sure we will meet as soon as possible to discuss 
future plans.
Mijn paranimfen Dr. Sarah Derks en Lotte Bakkerus.
Sarah, onze paden kruisten letterlijk op weg naar de poli interne geneeskunde in het 
VUmc. Als echte onderzoeker wilde ik graag met jou sparren over de kans om 
promotieonderzoek te doen. Ik wist dat ik deze kans met beide handen zou aangrijpen, 
toen bleek dat jouw - al net zo slimme - vriendin Tineke nauw betrokken was bij dit 
onderzoek. Dank je voor jouw scherpe analyses, tomeloze energie, en liefdevolle aan-
wezigheid op zoveel belangrijke momenten in de afgelopen jaren (inclusief de NY 
marathon finish!).
Lotte, jij kwam, zag en … regelde de boel. Als student solliciteerde je op een bijbaan 
als ondersteuner van ons onderzoeksteam. Al heel snel werd duidelijk dat je onmisbaar 
bent voor het ORCHESTRA onderzoek. Geen berg is je te hoog, inclusief de Stelvio! Ik ben 
ontzettend trots dat je je talenten nu ook als promovendus voor ons onderzoek inzet. 
Zonder jou had ik dit proefschrift nooit kunnen afronden. Je bent mijn rechterhand, maar 
bovenal heb je een bijzondere plek in mijn hart!
In 2013 werd de eerste patiënt in de ORCHESTRA studie in het VUmc geïncludeerd. 
Dit had niet gekund zonder de constructieve bijdrage van de oncologen, chirurgen, 
radiotherapeuten en interventieradiologen betrokken bij de multidisciplinaire zorg voor 
patenten met CRC in VUmc. In het bijzonder wil ik Babs Zonderhuis, Jurriaan Tuynman, 
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Geert Kazemier, Petrousjka van den Tol, Martijn Meijerink, Jan de Vries en Niels Haasbeek 
bedanken voor hun voortrekkersrol in deze trial. 
Babs, daarnaast steek jij ontzettend veel tijd in het medebeoordelen van de scans van 
de geïncludeerde patiënten. Dank voor je toewijding en prettige interactie met de 
promovendi en studenten die je daarvoor steeds aan de jas trekken.
Speciale dank aan de onderzoeksverpleegkundigen van het VUmc die zich in hebben 
gezet  voor de ORCHESTRA studie om, met in het bijzonder dank aan Rita en Annemarije 
voor voor hun hulp aan alle promovendi en studenten die in de loop van de jaren bij dit 
project betrokken waren.
Dank ook aan mijn mede-promovendi op de 3A gang; Claudia, Cyrillo, Dinja, Erik, Esther, 
Hanneke, Joeri, Joyce, Kathelijn, Lemonitsa , Liesbeth en Sophie voor gedeelde smart, een 
klankbord, gezellige lunches en elevator disco in Chicago. Esther mijn steun en toeverlaat 
in de onderzoekskamer, artsenkamer en op de Stelvio!
In de lab (aka croissant) meeting was de inbreng van Koen, Maria, Madelon, Robin, Richard 
en Henk vaak een lesje nederigheid als beginnend klinisch onderzoeker. Geweldig om 
van jullie te leren en enthousiast te raken over het lab onderzoek, waardoor dit ook een 
mooie plek in mijn promotietraject heeft gekregen. 
Dennis, jij hebt daarin een cruciale rol gespeeld. Je blijft graag onder de radar, maar 
ondertussen heb je ontzettend veel werk verzet in het onderzoek naar miRNAs in de 
ORCHESTRA samples. Fantastisch dat we onze samenwerking kunnen voortzetten in 
het RadboudUMC waar jij als PostDoc het translationeel onderzoek met de ORCHESTRA 
samples doet.
Meerdere promovendi van de afdeling oncologische chirurgie van het ErasmusMC 
hebben vol enthousiasme meegewerkt aan de inclusie van patiënten uit hun regio. Eric 
van der Stok, we hebben er in de beginjaren hard aan moeten trekken. Het is fijn dat je 
daar zoveel energie in wilde steken, ondanks dat het niet je eigen project was. Het heeft 
geleid tot een mooie gezamenlijke publicatie over de safety en feasibility data van de 
eerste 100 geïncludeerde patiënten in de trial.
Boris en Yannick volgden daarna met een net zo fijne samenwerking met Lotte, Lune en 
Mirthe. 
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Keer op keer werd ik verrast door slimme studenten zoals Marlou, Liselot, Nanneke, Tessa, 
Susan, Lune en Mirthe die kwamen helpen bij het coördineren van de trial en vaak in korte 
tijd zoveel betrokkenheid bij het project en de patiënten lieten zien.
In het lab van Professor Tom Würdinger worden ook samples van de patiënten in het 
ORCHESTRA onderzoek opgeslagen en geanalyseerd. Edward Post zorgt naast de 
analyses ook al jaren voor de correcte opvang van de samples en het distribueren van de 
verzendenveloppen. Een onmisbare schakel.
Professor Sleijfer en Dr. Jacco Kraan, dank voor jullie constructieve samenwerking in het 
onderzoek naar circulerende endotheelcellen in de samples van de ORCHESTRA patiënten 
uitgevoerd in het tumor immunologie lab van het ErasmusMC onder jullie leiding. 
Willemien Menke, mijn eerste stappen in het schrijven van een wetenschappelijk artikel 
zette ik met jou. Jouw kritische noot en nauwkeurige blik hielpen me om het onderwerp 
89Zr gelabeld Cetuximab PET imaging eigen te maken. Dankzij jouw precisie is dit gelukt, 
en kon je me ook nog de originele figuren uit het artikel na al die jaren met één druk op 
de knop doen toekomen.
Marc Huisman, Ronald Boellaard en Guus van Dongen, dank voor het delen van jullie 
expertise in het onderzoeksveld van PET imaging met radioactief gelabelde antistoffen. 
Emma Mulder, dank voor al het werk dat je in de analyse van de data hebt gestopt. Mooi 
om te zien dat deze onderzoeksvelden en de kliniek elkaar vinden en uiteindelijk dezelfde 
taal spreken in een mooie publicatie.
Dr. Beatriz Carvalho en Dr. Danielle Heideman, dank voor jullie begeleiding in mijn eerste 
stappen van het laboratorium onderzoek. Sandra Mongera, jij wees me letterlijk en 
figuurlijk de weg in het CCA en met de apparatuur en analyses. Dank voor je geduld en 
gezelligheid!
Mariette Labots, tijdens mijn stage als arts-assistent interne op de afdeling oncologie 
zag ik jou met een stikstof vaatje rondlopen na het opvangen van een biopt. Het liet de 
mogelijkheden zien van het combineren van de werkzaamheden als klinische dokter 
met het doen van wetenschappelijk onderzoek. Ik ben heel trots dat ik uiteindelijk ook 
zo’n pad heb kunnen bewandelen en daarin nauw met je heb kunnen samenwerken en 
veel van je heb kunnen leren! Ik ben dan ook vereerd dat je wilt opponeren tijdens het 
verdedigen van mijn proefschrift.
Inge Konings, bijzonder om van jou als mijn opleider medisch oncologie, uiteindelijk mijn 
registratie als oncoloog te mogen ontvangen.
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Professor van Herpen, beste Carla. Dank voor de mogelijkheid om als medisch oncoloog 
te komen werken op de afdeling medische oncologie van het RadboudUMC, met jou als 
afdelingshoofd. Het is een prachtige afdeling, waar ik sinds oktober 2019 met trots werk. 
Ik voel me op mijn plek in dit team van medisch oncologen. Dank jullie voor de welkome 
ontvangst en fijne samenwerking.
Dit geldt ook voor de afdelingen heelkunde, radiotherapie, interventieradiologie en 
pathologie in het RadboudUMC. Naast onze bestaande samenwerking in de ORCHESTRA 
trial, werken we nu ook samen in de dagelijks patiëntenzorg voor patiënten met 
gastrointestinale maligniteiten. Ik draag daar graag aan bij.
Alexander, Charlotte, Lieke en Lobke; al in het eerste jaar van onze studie geneeskunde 
ontmoetten we elkaar. Onze co-schappen in het MST in Enschede was als een seizoen 
‘Friends’. Naast vriendschap deel ik met jullie interesse in (gastro-intestinale) oncologie 
en wetenschappelijk onderzoek waardoor onze wegen ook professioneel blijven kruisen. 
Een bijzondere en waardevolle combinatie! Kim en Sanne, ook jullie waren al vanaf jaar 1 
in Groningen van de partij en blijven dat nog steeds daar in het hoge Noorden. 
Hannah, Joline, Laura, Noor, Marieke en Wietske;  onze band ontstond tijdens het buffelen 
als assistent interne in het SLAZ, waar we de werkdag doornamen tijdens een (of 2 of 3) 
rondjes Sloterplas en de week afsloten met een vrijmibo in de horeca van Amsterdam 
West… een heerlijk bestaan!
Dit promotieonderzoek heeft de afgelopen tien jaar een belangrijke plaats gehad in mijn 
werk als arts-onderzoeker. Het is heerlijk om daarnaast een fijn thuis te hebben. Ik heb 
het geluk een bijzondere band te hebben met mijn familie en schoonfamilie. Met hen 
deel ik naast de liefde voor elkaar ook de liefde voor muziek, kunst en natuur. Op onze 
heerlijke plek in Oosterbeek is hiervoor ruimte genoeg! Ik hoop op gauw weer zoete inval 
met muziek en houtoven pizza’s met hen en alle lieve vrienden die ergens mijn leven zijn 
binnengestapt.
Lieve Jos en Willem, jullie liefdevolle opvoeding heeft mij een vliegende start gegeven. 
Dankzij jullie volg ik het pad van mijn leven met een goed ontwikkeld moreel kompas en 
een gezonde dosis zelfvertrouwen. Ik ben er trots op deze mijlpaal met jullie te kunnen 
vieren. Lieve Gijs, Stefan en Anne-Marie - met wie zou ik liever op een onbewoond eiland 
willen zitten? Samen investeer ik graag in ons eilandje!
Lieve Pelle, met een stralende lach spring jij onbevangen in het diepe en zweef je de tuin 
door aan de kabelbaan die papa voor je gemaakt heeft. Lieve Jakob ik ben benieuwd wat 
het volgende project wordt!
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Deelnemende centra en lokale hoofdonderzoekers 
ORCHESTRA.
 
Amphia Hospital, Breda - Olaf Loosveld
Erasmus Medisch Centrum, Rotterdam – Kees Verhoef
Isala, Zwolle - Jan Willem B. de Groot
Radboud UMC, Nijmegen - Henk M.W. Verheul
Meander Medisch Centrum, Amersfoort - Joyce v Dodewaard
Noord West ziekenhuisgroep, Alkmaar - Mathijs P. Hendriks
Ziekenhuis Amstelland, Amstelveen - Annette A. v Zweeden
Fransiscus Gasthuis, Rotterdam - Danielle Mathijssen – van Stein 
Medisch Centrum Haaglanden, Den Haag, -  Helgi H. Helgason
Bravis ziekenhuis, Roosendaal - Frederiek Terheggen 
Elisabeth-TweeSteden ziekenhuis, Tilburg - Laurens V. Beerepoot
Antoni van Leeuwenhoek, Amsterdam - Cecile M.I. Grootscholten
Deventer Ziekenhuis, Deventer -  Hans Torrenga
Maasstad ziekenhuis, Rotterdam -  Brigitte C.M. Haberkorn
Jeroen Bosch ziekenhuis, Den Bosch - Hans F.M. Pruijt
IJsselland ziekenhuis, Capelle aan de IJssel -  Maarten Vermaas
Amsterdam UMC, Amsterdam - Kathelijn S. Versteeg, Pieter Tanis
Admiraal de Ruyter ziekenhuis, Goes - Henk van Halteren
Máxima Medisch Centrum, Eindhoven -  Ard Vreugdenhil
Sint Antonius ziekenhuis, Nieuwegein - Maartje Los
Medisch Centrum Leeuwarden, Leeuwarden - Marco B. Polée
Albert Schweitzer ziekenhuis, Dordrecht -  Marija Trajkovic-Vidakovic
Dijklander ziekenhuis, Hoorn - Marije M. Vleugel 
Gelre ziekenhuis, Apeldoorn - Hielke Meulenbeld
Onze Lieve Vrouwe Gasthuis, Amsterdam -  Jetske M. Meerum Terwogt
Ziekenhuisgroep Twente, Almelo– Ronald Hoekstra
Zaans Medisch Centrum, Zaandam - Sandra Bakker
Medisch Spectrum Twente, Enschede - Leonie J.M. Mekenkamp
University Hospital Southampton, Southampton -  John N. Primrose
University College London Hospital -  John Bridgewater
Dank ook aan alle oncologen, chirurgen, radiotherapeuten en interventieradiologen, 
onderzoeksverpleegkundigen en datamanagers in alle deelnemende ziekenhuizen die 
zich inzetten voor dit investigator initiated onderzoek in het belang van hun patiënten.
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Dit onderzoek had niet plaats kunnen vinden zonder de genereuze bijdrage van de 
Stichting Blokker-Verwer, waarvoor mijn speciale dank.
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CURRICULUM VITAE
Elske Christine Gootjes werd op 14 augustus 1980 geboren in Hardenberg en behaalde 
in 1998 haar VWO diploma aan het Vechtdalcollege aldaar. Na een semester  te hebben 
gestudeerd aan het University College te Utrecht kon ze in 1999 starten met de studie 
geneeskunde aan de RijksUniversiteit Groningen. Haar wetenschappelijk stage verrichte 
zij onder supervisie van Prof. C.H. Gips in de onderzoeksschool GISH-T, waarvoor zij drie 
maanden onderzoek deed in de Mayo Clinic in Rochester, Minnesota, VS onder supervisie 
van Prof. E.F.M. Wijdicks. Haar co-schappen liep zij in het Medisch Spectrum Twente, met 
een afsluitend co-schap in het Onze Lieve Vrouwe Gasthuis (OLVG) te Amsterdam. Na het 
artsexamen (2006, cum laude) werkte zij gedurende een jaar in het OLVG als arts-assistent 
Interne Geneeskunde, en deed zij ervaring op als arts-assistent psychiatrie bij Mediant 
te Enschede alvorens voor een jaar naar Australië te vertrekken. Daar werkte zij als arts-
assistent op de Eerste Hulp, afdeling Infectieziekten en Intensive care in respectievelijk het 
Prince of Wales hospital in Sydney en Lismore base hospital in Lismore, NSW. 
In januari 2009 startte zij met de opleiding Interne Geneeskunde van het VUmc (opleider 
Prof. Dr. Y.M. Smulders) en werkte in dat kader in het Sint Lucas Andreas Ziekenhuis, 
thans OLVG West, waarna zij in 2012 terugkeerde naar VUmc voor het afronden van de 
basisopleiding. 
Zij onderbrak haar opleiding in 2013 voor promotieonderzoek onder supervisie van prof. 
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